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Abstract
THE MOLECULAR MECHANISMS UNDERLYING THE CANCER KILLING EFFECT OF
INTERLEUKIN-24
by
Leah Eshanie Persaud
Advisor: Dr. Moira Sauane

Interleukin-24 (IL-24) is an immunomodulatory cytokine that also displays specific antitumor effects across many cancer cell types. The tumor suppressor activities of IL-24 include
inhibition of angiogenesis, metastasis, toxic autophagy, cancer-specific apoptosis, and
sensitization to traditional cancer treatments like chemotherapy and radiation. Overexpression of
IL-24 can selectively induce apoptosis in various cancer cells while having no adverse effects on
normal cells. Due to this favorable killing effect, IL-24 is currently in phase II clinical trials. There
is accumulating evidence that IL-24’s anti-cancer activity is primarily through the endoplasmic
reticulum (ER) stress pathway but other pathways leading to cell death are also exploited by IL24 depending on the cell type. In this work, in vitro studies were performed to understand the
downstream effects of IL-24-mediated ER stress such as eukaryotic initiation factor 2 alpha
(eIF2α) phosphorylation, which leads to ternary complex depletion and translation initiation
inhibition. We also uncover a novel mechanism of IL-24-mediated ER stress involving the protein
kinase A pathway and extrinsic apoptosis in breast cancer cell lines. Finally, we show for the first
time that endogenous IL-24 mRNA expression is affected by the differential expression of
microRNA-4719 and microRNA-6756-5p in castration-resistant prostate cancer cell lines
compared to normal or indolent prostate cancer cell lines. Each chapter of this work uncovers a
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new mechanism of action that can be applied to the development of anti-cancer therapeutics
involving IL-24. Understanding the intricacies of IL-24-mediated apoptosis in different cancer cell
line types will contribute to the development of personalized gene therapies that can target tumors
in a more safe and non-toxic approach.
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Chapter 1: Background
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1.1 Interleukin-24
In recent years, the pleiotropic cytokine, Interleukin-24 (IL-24), has become of special
interest as an anti-cancer therapeutic because of its selective killing effect on numerous cancer cell
types while having no effect on corresponding normal cells. IL-24, also known as melanoma
differentiation associated gene-7, is a part of the IL-10 family of cytokines and is endogenously
expressed by immune cells (myeloid, lymphoid, and monocyte) and epithelial cells (melanocytes
and keratinocytes) after stimulation with lipopolysaccharides or other cytokines (Andoh et al.,
2009; Buzas, Oppenheim, & Zack Howard, 2011; H Jiang, Lin, Su, Goldstein, & Fisher, 1995;
Maarof et al., 2010; Sainz-Perez et al., 2008; Wahl et al., 2009; Mai Wang, Tan, Zhang, Kotenko,
& Liang, 2002). IL-24 is found on the human chromosome 1q32-33 along with other cytokines of
the IL-10 family and it’s gene contains a signature sequence shared with IL-10 as well as a putative
secretory signal sequence (Huang et al., 2001). Specifically, IL-24 is grouped in the IL-20
subfamily along with IL-19, IL-20, IL-22, IL-24, and IL-26. As a secreted cytokine, IL-24 uses
IL-20R1/IL-20R2 or IL-22R2/IL-20R2 heterodimeric receptors to induce innate immunity
responses via signal transducer and activator of transcription 1 (STAT1) or STAT3 signaling
pathways (Dumoutier, Leemans, Lejeune, Kotenko, & Renauld, 2001; Sauane, Gopalkrishnan,
Sarkar, et al., 2003; Mai Wang et al., 2002).

1.2 Anti-cancer Activity of Interleukin-24
The pleiotropic nature of IL-24 was revealed when exogenous overexpression of IL-24
suppressed cancer cell growth and selectively induced apoptosis in tumors (Hongping Jiang et al.,
1996; Irina V Lebedeva et al., 2002). Since then, there have been positive studies establishing the
anti-cancer killing effect of IL-24 overexpression in different human cancer cell types including
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melanoma, glioma, nasopharyngeal carcinoma, neuroblastoma and carcinomas of lung, prostate,
breast, colon, ovaries, cervix, liver, bone and pancreas (Bhoopathi et al., 2016; Bhutia et al., 2011;
Sunil Chada et al., 2005; Fonseca-Camarillo, Furuzawa-Carballeda, Granados, & YamamotoFurusho, 2014; Gopalan, Shanker, Chada, & Ramesh, 2007; L. Li, Wang, & Wang, 2011; Y.-J. Li
et al., 2013; Lin et al., 2014; Pradhan et al., 2018; Xia et al., 2017; Xie et al., 2008; Xue et al.,
2006; A. Yacoub et al., 2008; J. Yang et al., 2019; Zheng et al., 2007). IL-24 has also been shown
to kill breast cancer-initiating stem cells by preventing their self-renewal properties (Bhutia, Das,
Azab, et al., 2013). Currently, IL-24’s normal physiological role has no relation to its anti-cancer
effects when it is overexpressed and delivered by adenovirus, cancer-specific oncolytic virus, or
recombinant fusion proteins. Also, there have been no studies detecting any significant killing or
toxic effects in normal cells due to IL-24 overexpression.
In addition to its selective apoptotic effect in tumor cells, IL-24 prevents angiogenesis,
invasion, and metastasis (Panneerselvam et al., 2015; Ramesh et al., 2003, 2004; Saeki et al., 2002;
Shi et al., 2007). IL-24 works synergistically with other anti-cancer treatments such as ZD55TRAIL, an oncolytic virus with the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) gene, bevacizumab, a monoclonal antibody against vascular endothelial growth factor
(VEGF), Herceptin (trastuzumab), a monoclonal antibody against human epidermal growth factor
2, and gefitinib, an epidermal growth factor inhibitor. (Cai, Liu, Huang, Zhang, & Liu, 2012;
Emdad et al., 2007; Inoue, Hartman, Branch, & Bucana, 2007; McKenzie et al., 2004).
Furthermore, IL-24 can sensitize tumors to other anti-cancer treatments including
chemotherapeutic agents, temozolomide and docetaxel, ionizing radiation, cisplatin, and
adenovirus-delivered p53. (Sunil Chada et al., 2018; G. Jiang et al., 2013; Kawabe et al., 2002;
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Mao et al., 2018; Z.-Z. Su et al., 2003; Wu et al., 2009; Adly Yacoub et al., 2003; Ming Yang et
al., 2018; Zheng et al., 2009).

1.3 Induction of Interleukin-24 Expression in Cancer Cells
IL-24 exhibits a bystander effect in which tumor cells treated with high levels of IL-24
recombinant protein is able to produce endogenous IL-24 to be secreted, subsequently killing
distant untreated cells (Sauane et al., 2008). Thus, IL-24 can regulate its own expression in cancer
cells when ectopically expressed. Other molecules such as microRNAs (miRNAs) have been
implicated in upregulating the expression of IL-24. One such molecule is miRNA-205 (miR-205)
whose expression is generally silenced or lowered in prostate and oral cancer cells (J. S. Kim et
al., 2013; Majid et al., 2010). When re-expressed in cancer cells, miR-205 induces the expression
of IL-24 by directly targeting regions of the Il-24 promoter leading to reduced cell migration and
invasiveness and increased cytotoxicity and apoptosis. These were the first studies to determine
that IL-24 could be regulated by miRNA at the transcriptional level.
More recently, a few studies have revealed that stimulation of specific proteins can activate
IL-24 production in cancer cells. Overexpression of coactosin-like protein (CLP/Cotl1), an Factin-binding protein whose expression is lost in prostate, breast and uterine cancers, was shown
to induce IL-24 expression in human MCF-7 breast cancer cells (Xia et al., 2017). Exogenous
expression of octamer-binding transcription factor 4 (OCT-4) increases IL-24 protein in breast
cancer cells and with the addition of ionizing radiation, further IL-24 was produced (J. Y. Kim,
Kim, Lee, & Park, 2018). Interestingly, the authors in this study report that IL-24 was involved in
inhibiting ionizing radiation-induced premature senescence in the OCT-4 expressing cancer cells
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rather than enhancing the effect of ionizing radiation, a previously reported function of IL-24 (Z.
Z. Su et al., 2006; Adly Yacoub et al., 2003).

1.4 Clinical Significance of Interleukin-24
Based on accumulating research, IL-24 is a promising tumor-suppressing therapeutic due
to its cancer-specific apoptotic, anti-angiogenic, anti-metastatic and synergistic properties proven
in vitro and in vivo. These favorable results gave rise to a Phase I clinical trial (NCT00116363)
examining the effect of intratumoral injections of replication-incompetent Ad.IL-24 (INGN 241)
in patients with 15 different types of cancers (Cunningham et al., 2005; Tong et al., 2005). The
study determined that all singly injected tumors exhibited Ad.IL-24 transduction and subsequent
increases in IL-24 mRNA, protein, and induction of cancer cell apoptosis closest to the injection
site. In addition, there was a widespread bioavailability of IL-24 protein away from the injection
site possibly supporting IL-24’s bystander effect seen in pre-clinical trials. Significant clinical
activity was seen in 44% of the lesions treated with repeated intratumoral injections, most
significantly in melanoma patients.
Despite the positive results seen in the clinic and the initiation of Phase II clinical trials,
use of IL-24 as an anti-cancer agent has been limited to repeat intratumoral injections in patients
with metastatic melanoma. It is evident that approaches to augment the therapeutic benefit and
clinical implementation of IL-24 are necessary to maximize its effectiveness and to extend the
significant results seen in melanoma to multiple cancer types.

1.5 Interleukin-24 Activates Endoplasmic Reticulum Stress
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The most common pathway in which IL-24 kills cancer cells involves molecules regulating
prolonged endoplasmic reticulum (ER) stress. The ER is the primary site of protein synthesis,
folding, and modification. Alterations in calcium storage, oxidative stress, glucose deprivation and
infection can disturb cellular homeostasis and cause ER stress. In the case of cancer, tumor cells
have a higher level of ER stress due to hypoxia, misfolded mutant proteins, and lack of nutrients
(Fels & Koumenis, 2014; Gerlach, Sharma, & Leister, 2012; Haynes, Titus, & Cooper, 2004). To
combat ER stress, the unfolded protein response (UPR) is activated to restore cellular homeostasis
by increasing folding capacity or protein degradation via inositol-requiring enzyme (IRE1)
stimulation, reducing the load of newly synthesized proteins via phosphorylation of eukaryotic
initiation factor 2 alpha (eIF2a) by protein kinase RNA-like endoplasmic reticulum kinase
(PERK), and translocating activating transcription factor 6 (ATF-6) to the nucleus to induce prosurvival mechanisms and increase transcription and folding of proteins (Healy, Gorman, MousaviShafaei, Gupta, & Samali, 2009).
Despite this, extreme and prolonged stress conditions of the ER can contribute to induction
of apoptosis, mainly through the increased expression of transcription factors such as activating
transcription factor 4 (ATF-4) via the PERK pathway, and ATF-6 and X-box binding protein
1(XBP1) via the IRE1 and ATF-6 pathways. All these transcription factors can subsequently
activate C/EBP-homologous protein (CHOP) to induce apoptosis. CHOP is a key apoptotic
mediator because it upregulates pro-apoptotic factors such as Bim and death receptor 5, which
leads to intrinsic apoptosis via the mitochondria and extrinsic apoptosis activation, respectively
(Mccullough et al., 2001; Puthalakath et al., 2007; Yamaguchi & Wang, 2004).
There is widespread evidence demonstrating that IL-24 activates prolonged ER stress to
induce apoptosis suggesting that this is IL-24’s main mechanism of action to kill cancer cells. For
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example, Ad.IL-24 has been shown to localize to the ER and Golgi apparatus in prostate cancer
cells (Sauane, Lebedeva, et al., 2004). This hypothesis was supported by previous studies in which
IL-24 activates p38 mitogen-activated protein kinase (p38 MAPK) to induce various growth-arrest
and DNA damage-inducible (GADD) genes associated with ER stress including CHOP, leading
to apoptosis in melanoma cells (Sarkar et al., 2002; X. Z. Wang et al., 1996). Later, it was shown
that p38 MAPK actually regulates the expression of IL-24 by stabilizing its mRNA in the 3’
untranslated region (3’UTR) (Otkjaer et al., 2010).
Mechanistically, IL-24 interacts with key players of the UPR to drive cancer cells toward
the path of apoptosis. For instance, IL-24 physically binds to the ER molecular chaperone, binding
immunoglobulin protein (BiP) in HeLa cells, which activates p38 MAPK and GADD genes
leading to cell death (Gupta et al., 2006). IL-24 can also activate the ER stress sensor PERK leading
to the activation of various pro-apoptotic pathways, buildup of cytosolic calcium, and generation
of ceramide and reactive oxygen species (ROS) in prostate cancer cells and primary malignant
glioma cells (Sauane et al., 2010; A. Yacoub et al., 2008; Adly Yacoub et al., 2011). Our lab has
revealed similar results in prostate cancer cells whereby IL-24 mediates apoptosis via ER stress by
binding and antagonizing sigma-1 receptor (Sig1R), a transmembrane ER chaperone protein
involved in calcium flux of the ER and mitochondria (Do et al., 2013). The IL-24:S1R interaction,
which can be inhibited by Sig1R agonists, is required for IL-24 to produce ROS emission, activate
caspase-3, mobilize calcium, and induce ER stress via BiP, CHOP, and eIF2a activation, leading
to cellular apoptosis.
While many studies reinforce the notion that IL-24’s cancer-specific killing effect initially
occurs through ER stress and the UPR, it is likely that IL-24 differentially utilizes molecular
mechanisms downstream or independent of ER stress to promote apoptosis in different cancer cell
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types. These mechanisms could be activated in varying degrees depending on the genetic profile
of tumor cells. For example, IL-24 is able to induce apoptosis in human glioma cells by activating
the pro-apoptotic protein, Bcl-2 associated X (BAX), while also killing DU145 prostate cancer
cells, which are BAX-negative and express low levels of Bak (Irina V Lebedeva et al., 2003;
Tamaki et al., 2014; A. Yacoub et al., 2008). IL-24 was also found to downregulate a subset of
cancer-promoting microRNAs (miRNAs) such as miR-200c, let7c, miR-320 and miR-221 leading
to toxic autophagy and then apoptosis in breast cancer cells (Pradhan et al., 2017).

1.6 Research Purpose
This dissertation focuses on how IL-24 exploits proteins from multiple signaling pathways
to induce its cancer killing effect and investigates the factors that may regulate IL-24 expression
to promote tumorigenicity in different cancer cell types. Due to IL-24’s activation of the ER sensor,
PERK, and subsequent phosphorylation of eIF2a to shut down translation, we hypothesize that
IL-24’s role as an ER stress modulator and tumor suppressor is linked to the inhibition of
translation initiation. To further uncover which proteins IL-24 modulates, protein kinase A (PKA)
was studied to determine whether it is an upstream regulator that mediates IL-24’s anti-cancer
effect via ER stress in breast cancer cell lines. Finally, putative miRNAs governing IL-24
expression were identified and explored to determine how IL-24 expression can be amplified to
increase its killing effect in prostate cancer cell lines. Before any therapeutic strategy is employed
in the clinic, the underlying molecular mechanism of action must first be studied preclinically in
cell lines, which is the rationale behind our chosen cell line models. The conclusions presented
here, however, would benefit from further testing in physiological models due to the limitations
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of cancer cell lines, which lack factors contributing to tumor microenvironments and tumor cell
heterogeneity (Wilding & Bodmer, 2014).
Fully understanding the downstream effects of IL-24 overexpression is essential to using
this pleiotropic cytokine for gene therapy. These insights will contribute to the development of
therapeutic targets that have the capacity to work synergistically with IL-24 or increase IL-24
expression, potentiating its killing effect in patients with cancers other than melanoma. This is
significant for translation into clinical research and drug development purposes since the most
substantial clinical results involving IL-24 have only been in melanoma patients (Cunningham et
al., 2005; Tong et al., 2005). In addition, revealing the mechanisms of IL-24-mediated apoptosis
can contribute to the use of IL-24 for personalized therapy. With advances in gene sequencing, it
will become more routine to sequence tumor cells to determine their mutational status and
personalize treatment options for patients. Understanding which proteins and pathways IL-24
affects to induce its cancer-specific killing activity will allow doctors to effectively prescribe
treatments that will only work if the required proteins necessary for its mechanism of action are
present and not mutated in a patient’s tumor. Accordingly, the goal of this work is to exploit the
molecular mechanisms and signaling pathways that IL-24 uses to induce apoptosis for the
development of a highly specific anti-cancer therapeutic.

9

Chapter 2: Materials and Methods
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2.1 Cell Culture and Conditions
Squamous cell carcinoma (KLN cells) expressing either wild-type (eIF2α-WT) or S51A
mutant eIF2α (eIF2α-S51A) were described previously (T. Chen et al., 2011; Denoyelle et al.,
2012). To determine if phosphorylation of eIF2α is necessary for the activity of IL-24 in the ternary
complex (TC) assay, endogenous eIF2α was replaced by either a non-phosphorylatable eIF2α
mutant (eIF2α-S51A) or a recombinant wild type eIF2α (eIF2α-WT).
KLN-tTA/pBISA-DL

(ATF-4)

engineered cancer cell lines that express Firefly luciferase (F-luc)

and Renilla luciferase (R-luc) open reading frames (ORFs) under the control of a bi-directional
promoter/enhancer complex was used for the dual luciferase TC assay. This assay was developed
to identify compounds that reduce the availability of the eIF2-GTP-tRNAiMet TC. Reduced
availability of TC inhibits translation of most mRNAs but paradoxically increases translation of
some mRNAs that contain multiple tandem upstream ORF in their 5’-untranslated regions
(5’UTRs). The reporter assay is bi-directional containing the minimal cytomegalovirus promoter
with R-luc on one side and F-luc on the other side flanked by a plasmid derived 5’UTR (90nt) and
the 5’UTR of ATF-4 (267nt) containing multiple tandem upstream ORFs (uORFs), respectively.
The R-luc mRNA is fused to a 5’UTR lacking any uORFs as previously described (T. Chen et al.,
2011; Denoyelle et al., 2012). Poly A tails are included on both sides for mRNA stability (Figure
3B). The reporters are detected using a dual luciferase assay and the expression levels are
expressed as the proportion of F-luc to R-luc luminescence where R-luc serves as an internal
control. This construct was transfected into KLN cells (KLN-luc) and confirmed to be highly
expressed under conditions where TC formation was limited using drugs that phosphorylate eIF2α
(B. H. Aktas et al., 2013).
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All other human cell lines (melanoma: WM35, MeWo; cervical cancer: HeLa; squamous
cell carcinoma: HO-1; breast cancer: MCF-7, MDA-MB-231, MDA-MB-157, T47D; prostate
cancer: PC-3, DU-145, Eoo6AA, E006AA-hT; normal prostate epithelial: RWPE-1) were
purchased from American Type Culture Collection (ATCC), maintained per ATCC protocols and
utilized within six months of thawing each vial. Cell lines were grown in a humidified atmosphere
at 37°C with 5% CO and culture media was replaced every other day.
2

2.2 Reagents
The PERK inhibitor I, GSK2606414 (EMD Millipore, Billerica, MA), was dissolved in
dimethyl sulfoxide (DMSO; Sigma–Aldrich), and stored at 100 µM. The final concentration to be
used was 0.5 µM GSK2606414. The PKR inhibitor C16, an imidizole-oxindole compound was
obtained from Sigma–Aldrich, dissolved in DMSO. The final concentration used was 2.5µM. Predissolved H-89 [N-(2-aminoethyl)-5-isoquinolino-sulfonamide] was purchased from EMD
Millipore (Darmstadt, Germany). PKI [L-threonyl-L-threonyl-L-tyrosyl-L-alanyl-L-a-aspartyl-Lphenylalanyl-L-isoleucyl-L-alanyl-L-serylgl ycyl-L-arginyl-L-threonylglycyl-larginyl-L-aspartic
acid] was purchased from Cell Signaling Technology (Danvers, Massachusetts) and rehydrated.
The final concentration used for H-89 and PKI was 10µM.

2.3 Virus Infection
After attachment within 24 h, cells were infected with the IL-24 expressing replication
defective adenovirus (Ad.IL-24) or the control, a corresponding empty adenovirus vector lacking
exogenous gene (Ad.vector). The adenoviruses were custom made by Vector Biolabs, Inc.
(Philadelphia, PA).
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2.4 Transfections of Oligonucleotides
Cells were seeded in 6-well plates. After reaching 60%-70% confluence, media was
replaced with Opti-MEM (Thermo Fisher Scientific Inc.; Wilmington, DE, USA) and cells were
transfected with either a 50nM non-targeting negative control oligonucleotide (MISSION®
Synthetic microRNA Negative Control, human, product# NCSTUD001), 50nM miR-4719
(MISSION® microRNA Mimic, human, product# HMI1756), miR-6756-5p oligonucleotide
mimic (MISSION® microRNA Mimic, human, product# HMI2362), 50nM miR-4719
(MISSION®

microRNA

inhibitor,

human,

product#

HSTUD1756)

or

miR-6756-5p

oligonucleotide inhibitor (MISSION® Synthetic microRNA Inhibitor, human, product#
HSTUD00363) (Sigma-Aldrich, St. Louis, MO, USA), using Lipofectamine RNAiMAX (Thermo
Fisher Scientific Inc.; Wilmington, DE, USA) according to the manufacturer’s instructions.
Transfected cells were then incubated at 37°C for a total duration of 24 h before cells were lysated.

2.6 MTT Assay
Prior to treatment, cells were plated at a concentration of 1000-2000 cells/well in 96-well
dishes with three replicates for each condition per cell line and allowed to attach for 24 h prior to
treatment(s). Cells were grown in their respective media with 10% FBS and 1% PenStrep and
attached for 12-24 h. After Ad.IL-24 treatment, cells were treated with inhibitors and media was
replaced after 72 h with fresh inhibitor. After 5 days of treatment, cell proliferation and viability
were determined by 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining
as previously described in (I. Lebedeva, Rando, Ojwang, Cossum, & Stein, 2000; Sauane,
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Lebedeva, et al., 2004). Absorbance was measured at 595nm using Tecan Spark 10M Microplate
Reader (Männedorf, Switzerland) and is proportional the number of living cells present.

2.7 Annexin V Binding Assay
After treatment, cells were detached using trypsin and washed with complete medium and
then PBS. Cells were then re-suspended in 500µL of binding buffer containing 2.5 mmol/L CaCl

2

and stained with allophycocyanin-labeled Annexin V (Becton Dickinson Biosciences, Palo Alto,
CA) and propidium iodide (PI) at room temperature for 15 min. Immediately after staining, flow
cytometry was performed as previously described (Sauane et al., 2008).

2.8 Wound Healing Assay
10,000 cells were seeded into 6-well plates. At 90% confluency, the cell monolayer was
wounded with a 200μL-pipette, washed with PBS and medium replaced with Opti-MEM with
treatments of either a 50nM non-targeting negative control oligonucleotide or 50nM miR-4719
oligonucleotide

mimic

or

miR-6756-5p oligonucleotide

mimic

or

50nM

miR-4719

oligonucleotide inhibitor or miR-6756-5p oligonucleotide inhibitor using Lipofectamine
RNAiMAX according to the manufacturer. Images were taken 24 h later. Images were taken using
Motic Images Plus 2.0 Software (Motic; British Columbia, Canada) from three experiments and
were analyzed for percentage cell-covered area.

2.9 Western Blot Analysis
Cellular protein was extracted using Pierce IP Lysis Buffer (Thermo Scientific, Rockford,
IL) and a mixture of Halt Protease Inhibitor Cocktail 100X (Thermo Scientific, Rockford, IL) and
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Phosphatase Inhibitor Cocktail 100X (Cell Signaling Technology, Danvers, Massachusetts). Fiftysixty micrograms of protein were applied to a 10% SDS/PAGE and transferred to nitrocellulose
membranes. Membranes were incubated with Odyssey blocking buffer (LI-COR Biosciences,
Lincoln, Nebraska) prior to incubation with polyclonal or monoclonal antibodies to phospho-S51
eIF2α, total eIF2α, CHOP, cyclin D1, cyclin E, survivin, Bcl2, a-tubulin, Glyceraldehyde 3phosphate dehydrogenase (GAPDH), Hsp27, c-jun, phospho-PKA substrates, PKA-C α subunit,
FasL, Fas, FADD, DR4, phospho-S15 TP53, total TP53, phospho-Thr180/Tyr182 p38 MAPK,
total p38 MAPK, phospho-S245 ATF-4, total ATF-4, BiP and β-actin overnight at 4°C. All
primary antibodies were purchased from Cell Signaling Technology (Danvers, Massachusetts)
except for phospho-S245 ATF-4 from Sigma Aldrich (St. Louis, MO). Goat anti-rabbit IgG (H+L)
800 CW, goat anti-rabbit (680 RD) and/or goat anti-mouse (H+L) secondary antibodies were
applied for 1 h at room temperature (1:25000, LI-COR) prior to washing with 1X Tris Buffered
Saline Tween-20 (TBS-T). Visualization was carried out with the LI-COR Odyssey CLx imaging
system and software.

2.10 cAMP Assay
MCF-7 cells were plated at a concentration of 5000 cells/well in Biocoat Poly-D-Lysine
96-well dishes. Cells were grown in Dulbecco Modified Eagle medium (DMEM) with 10% FBS
and attached 24 h prior to treatments. Production of cyclic adenosine monophosphate (cAMP) was
determined by the cAMP-Glo Assay by Promega (Madison, WI). Luminescence was measured
TM

using Tecan Spark 10M Microplate Reader (Männedorf, Switzerland).

2.11 Immunofluorescence
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Cells were plated onto chamber slides (Falcon; BD Biosciences, San Jose, CA) and
maintained per ATCC protocols. After 24 h of Ad.IL-24 infection and H-89 treatment, cells were
fixed with 2% paraformaldehyde, permeabilized by 0.1% Triton X-100, and then incubated with
phospho-Ser15 TP53 antibody. Incubation buffer was added to chamber slides as negative control.
After 2 washes with wash buffer, chamber slides were then incubated with Alexa Fluor 594
secondary antibody (Jackson Laboratory, Bar Harbor, ME) for 1 h at room temperature. After
rinsing with wash buffer, chamber slides were coated with DAPI anti-fade mounting medium (Life
Technologies, Grand Island, NY). DAPI-stained nuclei, cells were assessed on an inverted
fluorescent microscope (Nikon EclipseTi, Melville, NY) using 400X total magnification. Semiquantitative measurements of mean FITC intensity of cell nuclei were taken using NIS Elements
software whereby, the average intensity of five cells were taken under each experimental
condition.

2.12 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was isolated by using Qiagen RNeasy Mini Kit (Catalog Number 74104).
Reverse transcription was performed on 1μg of total RNA with an oligo(dT) primer using Qiagen
QuantiTect Rev. Transcription Kit (Catalog Number: 205311). cDNA corresponding to 20ng of
total RNA was amplified for 35 cycles by PCR using Thermo Fisher Applied
Biosystems™SYBR™ Green PCR Master Mix (Catalog Number: 4309155) with specific primers
as previously described (Sauane et al., 2010). Sequence-validated QuantiTec probes for bcl2,
survivin, cyclin D1, cyclin E, c-Myc, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and
β-actin purchased from Qiagen Bio-technology. Other primers used include: IL-24, FORWARD
5’-TTCTCTGGAGCCAGGTATC-3’,

REVERSE
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5-’TAGAATTTCTGCATCCAGGT-3,

GAPDH,

FORWARD

5’-AGCTTGTCATCAATGGAAAT-3,

REVERSE

5’-

CTTCACCACCTTCTTGATGT-3’.
MicroRNA isolation was performed using Invitrogen™ mirVana™ miRNA Isolation Kit,
with phenol, (Catalog Number: AM1560) according to manufacturer instructions. cDNA and qRTPCR were performed using Qiagen miScript II RT Kit (50) (Catalog Number: 218161) and Qiagen
miScript SYBR Green PCR Kits (Catalog Number: 218073), respectively. The following primers
®

were used: RNU6_B12 snRNA primers were purchased from Qiagen (Hs_RNU6-2_11 miScript
Primer Assay RNU6-6P RNA, U6 small nuclear 6, pseudogene: Product #218300, Catalog
Number: MS00033740). Hs_miR-4719_1 miScript Primer Assay and miR-6756-5p miScript
Primer Assay were purchased from Qiagen (hsa-miR-4719: Product # 218300, Catalog Number:
MS00033740) and (has-miR-6756-5p: Product # 218300, Catalog number: MS00046606).

2.13 Dual Luciferase Assay
Translation of reporter mRNAs harboring 5’UTR of human ATF-4 was monitored by dualluciferase assay as previously described (B. H. Aktas et al., 2013). Stably transfected KLN cells
with a bi-directional plasmid in which a common promoter/enhancer complex drives the
transcription of F-luc ORF fused to the 5’UTR of ATF-4, and of the R-luc ORF fused to a simple
90-nucleotide 5’UTR derived from the plasmid, were seeded in a six-well plate in triplicate and
the luciferase assay was performed at 48 h post infection with cells at 80% confluency. Cells were
collected in Passive Lysis Buffer, and F-luc and R-luc activities were measured using the Dualluciferase Reporter Assay kit (Promega, Inc., Madison, WI) according to the manufacturer’s
instructions. Experiments were repeated three times independently, whereby each biological
replicate consisted of a technical quadruplicate.
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2.14 Protein Synthesis
Total protein synthesis was measured as previously described (B. H. Aktas et al., 2013).
Briefly, wild-type (eIF2α-WT) or S51A mutant eIF2α (eIF2α-S51A) stable transfected cells were
seeded in six-well plates, serum starved for 16 h and then deprived of methionine and cysteine for
an additional 2 h using DMEM without the above amino acids (Gibco). Cells were then treated
with 10% serum containing 10μCi mL of S-Met/Cys (Perkin Elmer). Cells were lysed in RIPA
-1

35

buffer and protein concentration was determined by bicinchoninic acid assay (Pierce). Equal
amounts of protein were separated by SDS/PAGE or an aliquot of lysate was trichloroacetic acidprecipitated and counted in a scintillation counter (Beckman Coulter).

2.15 Statistical Analysis
Data was collected from at least three independent experiments. All results are presented
as mean ± standard error of the mean (SEM). Unless otherwise indicated, analysis of statistical
significance of differences between groups was performed using two-tailed Student’s t-test. Only
values with P < 0.05 were deemed statistically significant. Statistical differences in the relative
miRNA expression profiles were determined with one-way analysis of variance (ANOVA) using
the SPSS Statistics software (http://www-01.ibm.com/software/analytics/spss/) on normalized
data. Only values with P < 0.05 were considered statistically significant.
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Chapter 3: eIF2α Phosphorylation Mediates IL-24-Induced Apoptosis through Inhibition
of Translation

19

3.1 Introduction
Cancer is caused by loss of physiologic restraints on cell proliferation and survival.
Activation and/or amplification of proto-oncogenes, which cause uncontrolled cell growth, and
mutations and/or deletions of tumor suppressor genes, which allow the survival of pre-cancerous
cells, are prototypical examples of genetic aberrations that play a critical role in the development
and progression of cancer. Recent experimental and clinical studies indicate that perturbations of
some pathways associated with general cellular functions contribute to the genesis and progression
of cancer (Bjornsti & Houghton, 2004; Clemens & Bommer, 1999; Ruggero, 2013; Silvera,
Formenti, & Schneider, 2010). A paradigmatic example of such pathways is translation initiation,
which plays a critical role in the physiological regulation of cell proliferation, differentiation and
apoptosis (Bjornsti & Houghton, 2004; Clemens & Bommer, 1999). Unrestricted translation
initiation causes malignant transformation and critically contributes to the maintenance and
progression of cancers (Bhat et al., 2015; Pelletier, Graff, Ruggero, & Sonenberg, 2016; Ruggero,
2013; Silvera et al., 2010).
Altered expression of certain eukaryotic initiation factors (eIFs) can promote unrestricted
translation of specific groups of mRNAs that code for proteins involved in cancer cell survival,
proliferation, growth factors, and other tumor stimulating proteins (Bhat et al., 2015). A key eIF
that needs to be heavily regulated in cancer cells and influences the expression of mRNAs
responsible for oncogenic signaling is eukaryotic initiation factor 2 alpha (eIF2α).
Phosphorylation of eIF2α on serine 51 can impede translation initiation, a rate-limiting
step in protein synthesis, by binding to eIF2B, a guanine nucleotide exchange factor, to prevent
eIF2:GTP to form eIF2:GDP. This blocks the recruitment of the ternary complex (TC), which is
comprised of tRNA , GTP, and eIF2 alpha, beta, and gamma, and subsequently inhibits the
Met
i

20

formation of the pre-initiation complex (H Aktas et al., 1998; Huseyin Aktas & Halperin, 2004;
Benzaquen, Brugnara, Byers, Gattoni-Celli, & Halperin, 1995; S. S. Palakurthi, Aktas, Grubissich,
Mortensen, & Halperin, 2001; Sangeetha S. Palakurthi et al., 2000). Depletion of TC reduces the
overall rate of protein synthesis with a preferential effect on mRNAs encoding for oncogenic
proteins, and upregulates the expression of tumor-suppressor and pro-apoptotic proteins (Arrigo
De Benedetti & Graff, 2004; Willis, 1999). This paradigm is consistent with the recent recognition
that phosphorylation of eIF2α and the availability of TC control not only reduces the overall rate
of translation, as initially thought, but also reduces the expression of specific gene clusters.
Overexpression of eIF2α has been correlated with very aggressive lymphomas suggesting that its
dysregulation can contribute to cancer (Rosenwald et al., 2008; S. Wang et al., 1999). Thus, recent
cell and molecular biology work has confirmed the hypothesis that the translation initiation
machinery in general and TC in particular represent very attractive targets for the development of
mechanism-specific anti-cancer agents (J. Chu, Cargnello, Topisirovic, & Pelletier, 2016; Pain,
1996).
IL-24 is a tumor suppressing protein that is currently in phase II clinical trials. We and
others have shown that IL-24 releases calcium from ER stores (Do et al., 2013); induces ROS and
ceramide production (Sauane et al., 2006, 2010; Sauane, Gopalkrishnan, et al., 2004; Sauane,
Gopalkrishnan, Lebedeva, et al., 2003; Sauane, Lebedeva, et al., 2004) and induces inhibitory
phosphorylation of eIF2α (Pataer et al., 2002; Sauane et al., 2006, 2008). In addition, IL-24 is able
to increase the expression of downstream markers of TC availability such as binding
immunoglobulin protein (BiP) and C/EBP-homologous protein (CHOP) (Do et al., 2013; Gupta et
al., 2006; Harding et al., 2000). We also have demonstrated that Sigma 1 Receptor (Sig1R)
interacts with IL-24 and that IL-24:Sig1R is a critical upstream signal for IL-24-induced ER-stress,
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calcium mobilization, and notably, phosphorylation of eIF2α and apoptosis in cancer cells (Do et
al., 2013; Sauane et al., 2006, 2008, 2010; Sauane, Gopalkrishnan, et al., 2004; Sauane,
Gopalkrishnan, Lebedeva, et al., 2003; Sauane, Lebedeva, et al., 2004).
The present studies show that IL-24 causes phosphorylation of eIF2α in a wide variety of
cancer cells. Furthermore, our results indicate that IL-24 induces apoptosis through
phosphorylation of eIF2α, restricting the amount of the TC, and thereby inhibiting translation
initiation. These results demonstrate that eIF2α phosphorylation plays a major role in IL-24mediated apoptosis in cancer cells.

3.2 Results
3.2.1 IL-24-dependent phosphorylation of eIF2α is necessary and sufficient to mediate
apoptosis.
Translation in eukaryotic cells starts with the assembly of the eIF2-GTP-Met-tRNA ternary
complex, recruitment of the 40S ribosomal subunit, followed by binding to mRNA at its 5’UTR
end (W.-K. Chu, Dai, Li, & Chen, 2008; Hinnebusch, Ivanov, & Sonenberg, 2016; Pain, 1996).
The ribosomal complex then migrates along the 5’UTR of the mRNA in a process facilitated by
an array of initiation factors including eIF2 and eIF4 (W.-K. Chu et al., 2008; Hinnebusch et al.,
2016; Pain, 1996). At the end of each initiation event, GTP is hydrolyzed, and the eIF2-GDP
complex is released (Hinnebusch et al., 2016). Regeneration of the eIF2-GTP complex by a GDPGTP exchange reaction, catalyzed by eIF2B, is required to start a new round of translation
initiation. Phosphorylation of serine 51 in the α subunit of eIF2 inhibits GDP-GTP exchange,
suppressing the initiation of translation (Hinnebusch et al., 2016).
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We have previously demonstrated that IL-24 induces phosphorylation of eIF2α on serine
51 in prostate cancer (Sauane et al., 2008). Now we demonstrate that IL-24 also induces
phosphorylation of eIF2α on serine 51 (Figure 1A) in melanoma (HO-1, WM35, MeWo), breast
(MCF-7, MDA-MB-231) and cervical cancer cells (HeLa). Similarly, IL-24 exposure also reduced
viability of cancer cells (Figure 1B). The requirement for eIF2α phosphorylation for IL-24induced apoptosis was analyzed by IL-24 treatment of squamous cell carcinoma (KLN cells)
expressing either the wild-type (eIF2α-WT) or S51A mutant of eIF2α (eIF2α-S51A), the dominant
negative mutant of eIF2α. Compared with KLN cells expressing eIF2α-WT, eIF2α-S51A cells
were resistant to the inhibitory action of IL-24 on both cell growth (Figure 2A-C) and protein
synthesis (Figure 2D). These results show that phosphorylation of eIF2α is responsible for the
inhibitory effect of IL-24 on protein synthesis and cell growth.
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Figure 1. Effect of IL-24 on phosphorylation of eIF2α and proliferation in cancer cells. A. Melanoma (HO-1,
WM35, MeWo), breast (MCF-7, MDA-MB-231) and cervical cancer cells (HeLa) were treated for 48 h with Ad.IL24 (100 pfu per cell) or Ad.vector (100 pfu per cell). Cells were collected, protein purified, and subjected to Western
blot analysis to detect phospho-eIF2α protein. B. Cells were treated with Ad.IL-24 (100 pfu per cell) or Ad.vector
(100 pfu per cell), and cell viability was determined by the MTT proliferation assay, 5 days after treatment. Numbers
represent the ratio of specific treatments to values in control cells (Ad.vector). C. Cells were treated as described in
B, and then assayed for cell death using Annexin V staining a measure of apoptosis, was determined 48 h later by
FACS analysis using the CellQuest software (Becton Dickinson). An average of three independent experiments is
shown ± SD.
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Figure 2. IL-24-dependent phosphorylation of eIF2α is necessary to mediate apoptosis. A. Growth-inhibitory
effects of IL-24 in wild type eIF2α (left panel) or S51A mutant eIF2α (right panel) expressing cells. Cells were treated
with Ad.IL-24 (25, 50, or 100 pfu per cell) or Ad.vector (25, 50, or 100 pfu per cell), and cell viability was determined
by the MTT proliferation assay. Numbers represent the ratio of specific treatments to values in control cells
(Ad.vector). An average of three independent experiments is shown ± SD. B. Cells were treated as described in A,
and then assayed for cell death using Annexin V staining, a measure of apoptosis, was determined by FACS. C.
Induction of eIF2α phosphorylation protein after treatment with different concentrations of Ad.IL-24 was determined
by Western blot analysis. D. Wild type eIF2α or S51A mutant eIF2α expressing cells were serum starved for 16 h and
followed by 10% serum stimulation (FBS) with increasing concentrations of Ad.IL-24. Global protein synthesis was
monitored by S-Met/Cys incorporation.
35

3.2.2 IL-24 restricts formation of the ternary complex.
The availability of the TC not only determines the overall rate of translation initiation but
also differentially affects the translation of specific mRNAs. When TC is scarce, mRNA
translation is generally downregulated. Paradoxically, translation of some mRNAs such as ATF-4
mRNA is significantly more efficient under conditions that limit the availability of the TC because
their 5’UTRs contain multiple uORF (P. D. Lu, Harding, & Ron, 2004; Miao Wang & Kaufman,
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2014; Ye & Koumenis, 2009). To confirm that IL-24 restricts the abundance of the eIF2-GTPMet-tRNAi TC, we used a bi-directional plasmid in which a common promoter/enhancer complex
drives the transcription of Firefly luciferase (F-luc) ORF fused to the 5’UTR of ATF-4, and of the
Renilla luciferase (R-luc) ORF fused to a simple 90-nucleotide 5’UTR derived from the plasmid
(Figure 3A). The relative expression of each luciferase was established by the F-luc to R-luc ratio
determined in a dual luciferase assay (Bhat et al., 2015; Pelletier et al., 2016; Ruggero, 2013;
Silvera et al., 2010). In stably transfected KLN cells, IL-24 increased the F-luc to R-luc ratio in a
dose-dependent manner (Figure 3B), indicating that IL-24 increases translation of a multipleuORF 5’UTR (ATF-4) relative to translation modulated by a simple 90-nucleotide 5’UTR. To
validate IL-24 as a bona fide inhibitor of TC formation, we took advantage of the fact that reducing
the abundance of the TC upregulates CHOP mRNA and protein expression, a direct transcriptional
target of ATF-4. We measured the effect of IL-24 on KLN cells on the expression of CHOP mRNA
by quantitative-real time polymerase chain reaction (qRT-PCR) (Figure 3C) and CHOP protein by
Western blot (Figure 3D). Results of these secondary assays showed that IL-24 restricts formation
of TC and induces expression of both CHOP protein, and mRNA, without any effect on the
expression of the housekeeping β-actin gene.
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Figure 3. Identification and validation of IL-24 as modifier of the ternary complex abundance. A. The Firefly
luciferase (F-luc) ORFs and the Renilla luciferase (R-luc) ORFs were cloned into pBISA plasmid to transcribe two
reporter mRNAs. The 5’UTR of ATF-4 mRNA including first two codons of bona-fide ORF was cloned in frame with
respect to the start codon of F-luc ORF (pBISA-DL ). The mRNA products of pBISA-DL plasmid are shown. B.
KLN-tTA/pBISA-DL cells were incubated with the indicated concentrations of Ad.IL-24 (25, 50, or 100 pfu per
cell) and the normalized F/R ratio was determined by Dual-Luciferase Reporter Assay (Promega). C. KLNtTA/pBISA-DL cells were incubated with indicated concentrations of Ad.IL-24 and expression of endogenous
CHOP mRNA was determined by real-time PCR. D. IL-24 induces CHOP expression in KLN cells. KLN-tTA/pBISADL cells were incubated with the indicated concentrations of Ad.IL-24 (25, 50, or 100 pfu per cell) and expression
of endogenous CHOP protein was determined by Western blot analysis.
(ATF-4)

(ATF-4)

(ATF-4)

(ATF-4)

(ATF-4)

3.2.3 IL-24 preferentially inhibits expression of oncogenic proteins.
Expression of most proteins involved in cell proliferation and malignant transformation is
translationally controlled and is highly dependent on the activity of translation initiation factors
(Bhat et al., 2015; Clemens, 2004). To determine if IL-24 translationally downregulates expression
of oncogenic proteins, we performed Western blot and qRT-PCR analysis of lysates from
squamous-cell carcinoma cells treated with IL-24 or control (Ad.vector). Figure 4 shows that IL24 significantly reduced the expression of Bcl2, c-Myc, Survivin, Cyclin D1, and Cyclin E while
the expression of housekeeping proteins such as b-actin, GAPDH, a-tubulin, as well as Hsp27 and
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c-jun was not affected. Down-regulation of most oncogenic proteins was likely translational
because IL-24 has minimal effects on the levels of the respective mRNAs (Figure 4B). In eIF2αS51A cells that are resistant to its growth-inhibitory effect, Ad.IL-24 did not affect Bcl2, c-Myc,
Survivin, Cyclin D1, or Cyclin E expression (data not shown). These findings are consistent with
the view that inhibitors of translation initiation preferentially affect the expression of oncogenic
proteins.

Figure 4. IL-24 preferentially inhibits expression of oncogenic proteins. A. The wild type eIF2α or S51A mutant
eIF2α expressing cells were treated with Ad.vector (100 pfu per cell) or Ad.IL-24 (100 pfu per cell) for 72 h. Lysates
were prepared and probed with antibodies specific to Bcl2, Survivin, c-Myc, Cyclin D1, Cyclin E, a-tubulin, β-actin,
GAPDH, Hsp27, and c-jun. B. The wild type eIF2α or S51A mutant eIF2α expressing cells were incubated with
Ad.vector (100 pfu per cell) or Ad.IL-24 (100 pfu per cell) and expression of Bcl2, Survivin, c-Myc, Cyclin D1, Cyclin
E, a-tubulin and β-actin mRNA was determined by real-time PCR.

3.2.4 PKR and PERK in eIF2α phosphorylation induced by IL-24.
Pataer et al. demonstrated that IL-24 activates the double-stranded RNA-dependent protein
kinase R (PKR) in lung cancer cells (Pataer et al., 2005). Yacoub, A. et. al. demonstrated that
PKR-like endoplasmic reticulum-resident protein kinase (PERK) is activated by IL-24 treatment
in glioma cancer cells (A. Yacoub et al., 2008). Here, we explored whether PERK and/or PKR are
involved in IL-24-induced eIF2α phosphorylation. Figure 5 shows that IL-24 was partially unable
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to trigger eIF2α phosphorylation in the presence of PKR inhibitor 2-aminopurine or PERK
inhibitor, GSK2606414. These results indicate that PKR and PERK are necessary for IL-24mediated eIF2α phosphorylation.

Figure 5. IL-24-mediated activation of PKR and PERK. KLN cells were incubated with the PKR or PERK
inhibitors with or without Ad.IL-24 (100 pfu per cell) and expression of phoshpho-S51 eIF2α protein was determined
by Western blot analysis.

3.3 Discussion
The involvement of translation initiation factors in human cancers has been recognized
(Barna et al., 2008; J. Chu et al., 2016; Hinnebusch et al., 2016). Increased activation and/or
overexpression of translation initiation factors have been associated with transformation and
maintenance of cancer cell phenotype (Barna et al., 2008; Hsieh et al., 2012; Miluzio et al., 2011;
Weinstein, 2002). Inhibition of translation initiation could therefore be a powerful mechanism
harnessed for cancer therapy. The work reported here provides direct evidence that inhibition of
translation initiation with IL-24 induces apoptosis in cancer cells. Specifically, IL-24 induces
eIF2α phosphorylation, which reduces the abundance of the ternary complex (TC). Importantly,
we show that depletion of the TC by IL-24 results in the upregulation of pro-apoptotic proteins
such as CHOP. Thus, we provide the first direct evidence for translational control of gene-specific
expression by IL-24. This paradigm is consistent with the evolving notion in the field of
translational regulation of gene expression, phosphorylation of eIF2α, and the availability of TC
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control not only the overall rate of translation as initially thought, but also have differential effects
on the translation and expression of specific genes (Bhat et al., 2015). We show that through this
mechanism, IL-24 targets the expression of specific oncogenic proteins such as Bcl2, Survivin, cMyc, Cyclin D1, and Cyclin E, of which cancer cells depend on to maintain their transformed
phenotype. This approach has a clear advantage over the more generally genotoxic conventional
chemotherapy. On the other hand, though selective, IL-24 mediated inhibition of translation, is not
limited to targeting one single oncogene as other approaches do, but multiple oncogenic proteins,
which has the potential to circumvent the problem of resistance to treatment (Weinstein, 2002). It
is plausible that the effect of IL-24 on cell cycle regulation is also related to a broader effect of IL24, possibly involving molecular players other than eIF2α. IL-24-mediated inhibition of
translation initiation could be exploited for combination therapy with existing therapies that rely
on induction of eIF2α phosphorylation as primary or secondary targets or with mechanism specific
translation initiation inhibitors at various stages of development.
IL-24 is a pleiotropic cytokine that displays a broad range of activities including
antibacterial and antiviral responses, tissue remodeling, wound healing, and anti-tumor effects.
The effects of IL-24 seem to be quite complex because its role can vary depending on the cellular
source, target, and phase of the immune response. It remains unclear whether the antitumor effects
of IL-24 reflect its other biological functions. It is plausible that translation regulation has an
important role in IL-24’s other functions besides its anti-tumor activity, such as its antibacterial
and antiviral effects. In summary, the identification of translation initiation inhibition as a key
mediator of IL-24-cancer-specific apoptosis significantly broadens its therapeutic potential against
tumors.
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Figure 6: IL-24 activates the phosphorylation of eIF2α to inhibit translation initiation. Model illustrating the
possible molecular mechanism of cancer cell-selective apoptosis induction by IL-24 through inhibition of translation
in squamous cell carcinoma.
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Chapter 4: IL-24 Promotes Apoptosis through cAMP-Dependent PKA Pathways in Human
Breast Cancer Cells
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4.1 Introduction
Interleukin-24 (IL-24) is a member of the IL-10 protein family and displays broad cancerspecific suppressor effects (Cai et al., 2012; S Chada et al., 2006; L. Li et al., 2011; Owen, Ruge,
& Jiang, 2015; Ramesh et al., 2003, 2004; Saeki et al., 2002; Sauane, Lebedeva, et al., 2004).
Notably, clinical and pre-clinical studies have indicated that IL-24 displays prominent antitumor
action (Cunningham et al., 2005; Menezes et al., 2018; Tong et al., 2005). The tumor suppressor
activities of IL-24 include inhibition of angiogenesis, invasion, and metastasis, sensitization to
chemotherapy, and induction of cancer-specific apoptosis. Given its ubiquitous apoptotic effect on
malignant cells, lack of an effect on normal cells, and absence of significant side effects, IL-24 is
an important candidate for cancer therapy.
We have shown that overexpression of IL-24 is implicated in endoplasmic reticulum (ER)
stress-mediated apoptosis in cancer cells (Do et al., 2013). We have demonstrated that IL-24
activates protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), one of three
canonical ER-stress response pathways (Persaud et al., 2017). PERK phosphorylates the alpha
subunit of the eukaryotic translation initiation factor 2 (eIF2α) which inhibits translation initiation
while inducing expression of activating transcription factor 4 (ATF-4) and DNA damage-inducible
transcript 3, also known as C/EBP homologous (GADD153/CHOP) proteins. Thus, the
PERK/eIF2α /ATF-4/CHOP axis appears to be essential for induction of apoptosis by IL-24.
Previous studies have shown that protein kinase A (PKA) can also induce ATF-4 expression
leading to apoptosis in human liver carcinoma cells after treatment with palmitate, a saturated fatty
acid implicated in ER stress (Cho et al., 2013).
PKA is a serine/threonine kinase that phosphorylates a multitude of proteins in response to
fluctuations in cyclic 3',5'-adenosine monophosphate (cAMP) levels. PKA is a holoenzyme
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consisting of two catalytic subunits that bind a dimer of identical regulatory subunits (Sapio et al.,
2014). Under basal conditions, PKA is inactive but can become activated when cAMP levels rise
in response to various stimuli. Once cAMP binds to the PKA regulatory subunits, PKA catalytic
subunits are released as active monomers, which then catalyzes substrate phosphorylation. The
cAMP-PKA signaling integrates downstream pathways to regulate numerous cellular responses
including cell proliferation and survival, metabolism, cell cycle regulation, cytoskeleton
remodeling, and ion channel regulation.
In terms of ER stress and ATF-4 activation, after the delayed activation of PKA by
palmitate, ATF-4 interacts with cAMP-responsive element-binding protein 1 (CREB1), a
downstream target of PKA, to bind to the ATF-4 promoter leading to sustained ATF-4 protein
expression (Cho et al., 2013). It is suggested that this feedback loop involving activated PKA is
necessary for the induction of apoptosis via ER stress and CREB1 phosphorylation. In addition, it
has been shown that inhibition of PKA by H-89 prevents ATF-4 and CHOP induction in cells
treated with exendin-4, a glucagon-like peptide 1 receptor agonist (Yusta et al., 2006). Due to
effect of PKA on ATF-4, a key target in the ER stress pathway, and the role of PKA as a key
growth regulator, we hypothesize that PKA is an upstream mediator of IL-24 killing activity and
may regulate several of IL-24 downstream signaling pathways including ATF-4 activation.
In this study, we document for the first time that PKA plays a role in IL-24-mediated
apoptosis. These studies define PKA as a key mediator of IL-24 induction of ATF-4 activation,
extrinsic apoptosis, activator of TP53, and p38 mitogen-activated protein kinase (p38 MAPK).
These findings are important in our knowledge of IL-24 as a tumor suppressor protein as well as
an immunomodulatory cytokine.
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4.2 Results
4.2.1 IL-24 regulates expression and phosphorylation of ATF-4.
We have recently shown that IL-24 inhibits translation initiation by phosphorylating eIF2a
during ER stress (Persaud et al., 2017). Despite this, it is unclear why lL-24 induces its apoptotic
effect through ER stress mechanisms. ER stress activates both pro-survival and pro-apoptotic
pathways, however, a particularly strong or prolonged ER stress can overwhelm pro-survival
mechanisms, tipping the balance toward apoptotic pathways, thus preventing tumor development,
growth, and invasion. Multiple studies show that different environmental and physiological
stresses can affect the duration and level of eIF2α phosphorylation, and ATF-4 induction and
protein interactions determining cell outcome. (Mccullough et al., 2001; Puthalakath et al., 2007;
Yamaguchi & Wang, 2004).
Therefore, we analyzed whether IL-24 affects the expression of ATF-4. We treated MCF7 human breast cancer cells with increasing concentrations of adenovirus vector expressing IL-24
(Ad.IL-24) for 72 h and analyzed expression of ATF-4 protein by Western blot. As shown in Figure
7, IL-24 induced both ATF-4 expression and ATF-4 phosphorylation on serine 245. It has been
shown that phosphorylation of ATF-4 at the serine residue 245 upregulates ATF-4 transcriptional
activity (Hao et al., 2016). We also show that in MCF-7 cells, IL-24 activates binding
immunoglobulin protein (BiP), a downstream marker of ATF-4 activation in a concentration
dependent manner (Takayanagi, Fukuda, Takeuchi, Tsukada, & Yoshida, 2013).

35

Figure 7. IL-24 activates ATF-4 in a dosage dependent manner. MCF-7 cells were treated for 72 h with Ad.IL-24
(25, 50, and 100 plaque-forming units (pfu) per cell) or Ad.vector (100 pfu per cell). Cells were collected, protein
purified, and subjected to Western blot analysis to detect phospho-ATF-4, total ATF-4, BiP and β-actin.

4.2.2 IL-24-mediated activation of PKA.
ATF-4 expression is induced at the translational level due to eIF2a phosphorylation and at
the transcriptional level due to PKA activity (Cho et al., 2013; Pataer et al., 2005; Persaud et al.,
2017). To determine if IL-24 activates PKA, we examined the profiles of known downstream
substrates of PKA which are phosphorylated on PKA-specific serine or threonine residues. We
found that with increasing concentrations of IL-24, phosphorylation levels of PKA substrates
substantially increased 72 h post-infection in MCF-7 breast cancer cells (Figure 8A). We attribute
this increase in substrate phosphorylation to PKA activation rather than increased expression of
PKA protein, since the protein levels of the PKA catalytic α subunit remained unchanged despite
increasing levels of IL-24 (Figure 8A). This IL-24-mediated activation of PKA is reversed in
response to PKA inhibitor, H-89 (Figure 8C). Cyclic 3',5'-adenosine monophosphate (cAMP)
levels, which is a known activator of PKA, also increases in a concentration dependent manner
after treatment with IL-24 (Figure 8B). To determine whether PKA is involved in the activation
of ATF-4, we used PKA inhibitor H-89, in conjunction with IL-24 treatment. Figure 8D shows a
decrease in ATF-4 phosphorylation at serine 245 when IL-24 is overexpressed and PKA is
inhibited demonstrating the involvement of PKA in IL-24 activation of ATF-4.
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Figure 8. IL-24 activates PKA in a concentration dependent manner. A. MCF-7 cells were treated for 72 h with
Ad.IL-24 (25, 50, and 100 pfu per cell) or Ad.vector (100 pfu per cell). Cells were collected, protein purified, and
subjected to Western blot analysis to detect phospho-PKA substrates, PKA-Ca subunit and β-actin proteins. B. MCF7 cells were treated with Ad.vector (100pfu/cell) or Ad.IL-24 (25, 50, and 100 pfu per cell) and then assayed for the
production of cAMP after 20 h of treatment. Numbers represent mean cAMP (nM) concentration after normalization
to control. An average of three independent experiments is shown ± SE (n=9). C-D. MCF-7 cells were treated for 72
h with Ad.vector (control) or Ad.IL-24 at 100 pfu/cell and either untreated or treated with 10μM H-89 for 72 h. Cells
were collected, protein purified, and subjected to Western blot analysis to detect phospho-PKA substrates, PKA-Ca
subunit, phospho-ATF-4, total ATF-4 and β-actin.

4.2.3 Inhibiting PKA activity abrogates IL-24 killing effect.
Next, we explored whether PKA is involved in IL-24-induced apoptosis in breast cancer
cells. To test this hypothesis, we treated several human breast cancer cell lines (MCF-7, T47D,
MDA-MB-157 and MDA-MB-231) with IL-24 in the presence or absence of the specific PKA
inhibitors, H-89 and PKI. Cell viability and induction of apoptosis was measured by MTT and
Annexin V-FITC/PI assays, respectively. As shown in Figure 9, H-89 and PKI inhibited IL-2437

mediated killing in all breast cancer cell lines. Taken together, these results suggest that PKA is
necessary for IL-24-induced apoptosis. It has been previously demonstrated that IL-24 selectively
kills cancer cells through p38 MAPK signaling (Sarkar et al., 2002). Because p38 MAPK
participates in the regulation of the ER stress signaling, we hypothesized that PKA may be
involved in IL-24 activation of p38 MAPK. As shown in Figure 9C, IL-24 activates p38 MAPK
at threonine 180 and tyrosine 182 in MCF-7 cells. To validate that PKA plays a role in IL-24mediated activation of p38 MAPK, we used H-89 in conjunction with IL-24 treatment and found
that the inhibition of PKA prevents the activation of p38 MAPK over 24 h suggesting that p38
MAPK signaling pathway is downstream of PKA (Figure 9D).
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Figure 9. The IL-24 killing effect is decreased in the presence of PKA inhibitors. A. Human breast MCF-7, MDAMB-231, MDA-MB-157, and T47D cancer cells were incubated with 10 μg of PKA inhibitor, H-89, or PKI, with or
without Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu per cell), and cell viability was determined by the MTT
proliferation assay five days after treatment. Numbers represent the ratio of specific treatments to values in control
cells (Ad.vector). An average of three independent experiments is shown ± SD as errors bars. *, p < 0.001 compared
to Ad.vector. B. Cells were treated as described in A, and then assayed for cell death using annexin V staining, a
measure of apoptosis, was determined 48 h later by fluorescence-activated cell sorting (FACS) analysis using the
CellQuest software (Becton Dickinson). An average of three independent experiments is shown ± SD as errors bars,
*, p < 0.001 compared to Ad.vector. C. MCF-7 cells were treated for 24 h with Ad.IL-24 (25, 50, and 100 pfu per
cell), 10 μg H-89 or Ad.vector (100 pfu per cell). Cells were collected, protein purified, and subjected to Western blot
analysis to detect phospho-p38 MAPK, total p38 MAPK, and β-actin. D. MCF-7 cells were infected with either
Ad.vector (control) or Ad.IL-24 at 100 pfu/cell, and either untreated or treated with 10 μg H-89 for 72 h. Western blot
analysis was performed with antibodies for phospho-p38 MAPK, total p38 MAPK, and β-actin.
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4.2.4 IL-24 activates TP53, a downstream target of PKA activity.
Previous studies have shown that IL-24 is able to activate TP53 in breast cancer,
hepatocellular carcinoma and chronic lymphocytic leukemia cells (Sainz-Perez et al., 2008; Xue
et al., 2006; Zheng et al., 2009). However, until now, there is no evidence showing that IL-24
activates PKA to regulate TP53 activity in cancer cells. Here, we show that IL-24 induces TP53
expression, increases its phosphorylation on serine 15 (phospho-Ser15 TP53) and promotes
nuclear translocation in MCF-7 breast cancer cells in a PKA-dependent manner (Figure 10). It is
known that nuclear translocation of phospho-Ser15 TP53 plays a critical role in the regulation of
cell cycle arrest, apoptosis, and cellular senescence in cancer cells (Amano et al., 2009; Bean &
Stark, 2001; Fiscella et al., 1993; S. Y. Shieh, Ikeda, Taya, & Prives, 1997; Siliciano et al., 1997;
Unger et al., 1999; Webley et al., 2000; Y. Zhang & Xiong, 2001). Our results reveal that in
response to IL-24, phospho-Ser15 TP53 translocates from the cytoplasm into the cell nucleus
compared to Ad.vector and H-89 reduces this translocation (Figure 10C). Taken together, these
results suggest that IL-24-induced TP53 expression, phosphorylation and nuclear localization is
mediated by PKA activity.
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Figure 10. IL-24 induces TP53 expression and promotes nuclear translocation in a PKA-dependent manner.
A,B. MCF-7 cells were treated for 72 h with Ad.IL-24 (25, 50, and 100 pfu per cell), 10μM H-89, or Ad.vector (100
pfu per cell). Cells were collected, protein purified, and subjected to Western blot analysis to detect to detect phosphoTP53, total TP53, and β-actin proteins. C. Semi-quantitative measurements of the mean fluorescein isothiocyanate
(FITC) intensity were taken using Nikon NIS Elements whereby, the average intensity of five cell nuclei were taken
under each experimental condition. Error bars are expressed as the standard deviation of FITC intensity values. D.
Cells were fixed and phospho-Ser15 TP53 was detected by immunofluorescence using anti-phospho-TP53 primary
antibody and anti-rabbit secondary antibody conjugated to FITC.

4.2.4 PKA activation mediates IL-24 extrinsic apoptotic effect.
IL-24 treatment is known to induce expression of various members of the extrinsic
apoptotic pathway such as Fas cell surface receptor (Fas), Fas ligand (FasL), Fas-associated death
domain (FADD) in human ovarian cancer cells and death receptor 4 (DR4), in colorectal cancer
cell lines (Gopalan, Litvak, Sharma, Mhashilkar, & Chada, 2005; L Zhao et al., 2006). Based on
these studies, we sought to determine whether IL-24 activates the extrinsic pathway of apoptosis
in MCF-7 breast cancer cells and if the IL-24 induction of extrinsic apoptotic pathway is PKAdependent. IL-24 infection did indeed increase Fas, FasL, DR4, and FADD levels in MCF-7 cells
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within 72 h (Figure 11A). The increase in expression of the molecular markers associated with the
extrinsic apoptotic pathway was blocked by H-89 (Figure 11B). Taken together, these results
suggest that PKA is necessary for IL-24-induced extrinsic apoptotic pathway.

Figure 11. Inhibition of PKA blocks IL-24 activation of extrinsic apoptosis. A. MCF-7 cells were infected with
either Ad.vector (control) or increasing concentrations of Ad.IL-24 (25, 50, 100 pfu per cell) for 72 h. Western blot
analysis was performed with antibodies for FasL, Fas, FADD, DR4 and β-actin. B. MCF-7 cells were infected with
either Ad.vector (control) or Ad.IL-24 at 100 pfu/cell and either untreated or treated with 10μM H-89 for 72 h. Western
blot analysis was performed with antibodies for FasL, Fas, FADD, DR4 and β-actin.

4.3 Discussion
Based on the positive results from pre-clinical and Phase I clinical trials (Cunningham et
al., 2005; Tong et al., 2005), IL-24 has been transitioned into a phase II clinical trial, indicating
that it is has the potential to be safe and effective for cancer gene therapy. There is plenty of
evidence validating the antitumor role of IL-24 whereby it induces cancer-specific apoptosis,
inhibits tumor angiogenesis and metastasis, and regulates anti-tumor immune responses (Do et al.,
2013; Hongping Jiang et al., 1996; Irina V Lebedeva et al., 2002; Ramesh et al., 2003, 2004; Saeki
et al., 2002; Sauane et al., 2006; Sauane, Lebedeva, et al., 2004). We have shown that Ad.IL-24
and IL-24 protein, produced by Ad.IL-24-infected cells, display extensive cancer-specific proapoptotic activity by stimulating ER stress and ceramide production in prostate cancer cells with
no effect on normal prostate epithelial cells (Sauane et al., 2010). Secreted IL-24 protein also
generates a strong expression of endogenous IL-24 and subsequent induction of tumor-specific
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killing by ER stress activation and reactive oxygen species production (Do et al., 2013). IL-24 also
inhibits angiogenesis in human lung tumor cells in vivo and sensitizes breast cancer cells to
chemotherapy (S Chada et al., 2006; Ramesh et al., 2003). More recently, we have shown that IL24-triggered-phosphorylation of eIF2a reduces the availability of the ternary complex in
squamous cell carcinoma KLN cells and preferentially represses expression of oncogenic proteins
(Persaud et al., 2017).
Although signaling pathways triggered by IL-24 have been the focus of intensive studies
for over 20 years, the mechanisms governing cancer-specific apoptosis triggered by IL-24 are still
not well understood. The results presented here identify PKA as a key mediator of cancer-specific
killing by IL-24. For the first time, we show that IL-24 increases intracellular cAMP levels and
activates PKA to exert its killing effect through the extrinsic apoptotic pathway in MCF-7 breast
cancer cells (Figure 12). IL-24 elevates cAMP levels in a concentration dependent manner
resulting in PKA activation and increases phosphorylation of PKA substrates (Figure 8A-B). Cell
viability and Annexin V analysis shows that cancer cell killing by IL-24 is dependent on PKA, as
chemical inhibition of PKA by H-89 abrogates pro-apoptotic activity of IL-24 on cancer cells
(Figure 9). In addition, PKA plays a role in IL-24 mediated ER stress as evidenced by activation
of ATF-4 (Figure 7).
We observe for the first time that in response to IL-24 treatment, PKA plays a role in
extrinsic apoptotic pathway. When MCF-7 breast cancer cells are treated with IL-24, key players
in the Fas signaling pathway such as the Fas, FasL, and FADD are upregulated, supporting
previous studies that IL-24 activates apoptosis extrinsically in cancer cells (Gopalan et al., 2005;
Shanker et al., 2007; L Zhao et al., 2006). With the addition of PKA inhibitor H-89, these apoptotic
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signaling proteins are downregulated indicating that induction of extrinsic apoptotic pathways by
IL-24 is mediated by PKA (Figure 11).
In human cancer, tumor suppressor TP53, possesses high mutation rates and its inhibition
or absence is critical driving cancer formation and progression. We reveal for the first time that
PKA activation is necessary for IL-24 activation of TP53 at serine 15 (phospho-Ser15 TP53)
(Figure 10B). Phospho-Ser15 TP53 is known to localize to the nucleus to activate cell-cycle arrest
and apoptosis in cancer cells (Fiscella et al., 1993; Unger et al., 1999; Webley et al., 2000). Here,
we provide evidence that phospho-Ser15 TP53 localizes to the nucleus after IL-24 treatment in
MCF-7 cells (Figure 10C). This localization to the nucleus is also dependent on the activity of
PKA. Earlier studies have established that IL-24 activates TP53 in MDA-MB-453 breast cancer
cells and HepG2, MHCC97L and Hep3B hepatocellular carcinoma cells (Xue et al., 2006; Zheng
et al., 2009). As shown in Figure 9, IL-24 inhibits the growth of different breast cancer cells lines
containing wild-type TP53 (MCF-7), mutant TP53 (MDA-MB-231 and T47D), or null TP53
(MDA-MB-157). While we have shown that IL-24 can induce apoptosis independent of TP53,
the molecular mechanisms underlying the activation of TP53 triggered by IL-24 could be relevant
for the development of precise therapeutics that use IL-24 in combination with compounds that
reactivate mutant TP53 to wild-type TP53 to suppress tumors (X. Yu, Narayanan, Vazquez, &
Carpizo, 2014). These small molecule drugs, which have been tested in pre-clinical and Phase I
trials, can specifically target mutant forms of TP53 to reactivate its structural stability or restore
its transcriptional activity. Future studies examining the synergistic effects of IL-24 and these
compounds can uncover new treatment options for patients that have tumors with mutated TP53
gene profiles.
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Overall, these results suggest that PKA is a key mediator of IL-24-induced apoptosis in
breast cancer cells. Specifically, we reveal that PKA mediates several pathways, including p38
MAPK, p53, ER stress, and extrinsic apoptosis, which are known to be activated by IL-24 to
specifically kill cancer cells. The evidence presented here points to PKA as a possible upstream
regulator that potentiates IL-24 killing of cancer cells. Understanding the complexities of IL-24
induction of apoptosis in cancer cells significantly broadens its potential as an anti-tumor
therapeutic and reveal new combinatorial strategies for targeted cancer therapies.

Figure 12: IL-24 activates PKA to induce apoptosis in breast cancer cells. Schematic of the molecular mechanisms
underlying Ad.IL-24 induced apoptosis of cancer cells, involving PKA activation, ATF-4 phosphorylation, p38MAPK
signaling, p53 phosphorylation, Fas apoptotic signaling, and inhibition of translation initiation.
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Chapter 5: MicroRNA-4719 and microRNA-6756-5p correlate with castration-resistant
prostate cancer progression through Interleukin-24 regulation
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5.1 Introduction
Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause
of cancer-related death for men in the USA (Katsogiannou et al., 2015; Parnes, House, & Tangrea,
2013; Siegel, Miller, & Jemal, 2017). Accounting for 180,890 new cases in the United States in
2016, PCa is a major cause of cancer morbidity and mortality (Katsogiannou et al., 2015; Parnes
et al., 2013; Siegel et al., 2017). The annual morbidity grows as the rate of PCa has increased by
14% over the last two decades (DeSantis et al., 2016; Luu et al., 2017; Wadhwa & Dumbre, 2016).
Despite this, men with PCa do not die from localized prostate cancer but instead, castrationresistant prostate cancer (CRPC) (DeSantis et al., 2016; Luu et al., 2017; Wiklund, 2010). In the
US, the average 5-year survival rate for localized PCa is 100%, but for CRPC it is less than 30%
(Moyer, 2012; Obinata, Takayama, Takahashi, & Inoue, 2017; Wiklund, 2010). Prostate specific
antigen, the current tool for screening for PCa, is highly controversial because it is not PCa-specific
and has a high false positive rate (Moyer, 2012; Obinata et al., 2017; Wei et al., 2014; Wiklund,
2010). Consequently, new biomarkers are urgently needed for the early detection of PCa, and it is
crucial that these novel biomarkers are sensitive enough to discriminate between indolent PCa and
CRPC.
Interleukin-24 (IL-24), also known as melanoma differentiation associated gene-7, is a
multifunction cytokine that has been studied for its specific anti-cancer properties. Along with
killing other cancer cell types, IL-24 induces apoptosis in PCa cells through endoplasmic reticulum
(ER) stress, mitochondrial dysfunction, reactive oxygen species (ROS) emission, and
downregulation of anti-apoptotic proteins (Bhutia et al., 2010; Do et al., 2013; Irina V Lebedeva
et al., 2003; Sauane et al., 2008, 2010; Tian et al., 2012). In combination with treatments such as
ionizing radiation and Sabutoclax, IL-24 can also sensitize PCa tumors to apoptosis (Dash et al.,
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2011; Z. Z. Su et al., 2006). While several in vitro and in vivo studies have characterized IL-24 as
specific cancer killing protein in PCa cells compared to normal prostate epithelial cells (Bhutia et
al., 2010, 2011, Dash et al., 2010, 2011; Do et al., 2013; Irina V. Lebedeva et al., 2003; Majid et
al., 2010; Mao et al., 2018; Sauane et al., 2010; Sauane, Lebedeva, et al., 2004; Z. Z. Su et al.,
2006; J. Yang et al., 2019; D.-D. Yu et al., 2015), IL-24 expression in PCa, is not fully understood.
Here, we seek to understand the factors that may increase IL-24’s short mRNA half-life leading to
the upregulation of IL-24 protein and thus, increased apoptosis in PCa and CRPC cell lines.
Uncovering the factors and potential mechanisms that may regulate IL-24 mRNA expression in
cancer cells is important to understand how IL-24 can be developed as an anti-cancer therapeutic.
MicroRNAs (miRNAs) are 20-24-nucleotide-short RNAs that play pivotal roles in almost
all biological processes in mammalian species (Iorio & Croce, 2012; J. Lu et al., 2005; MacFarlane
& R. Murphy, 2010). It is well established that miRNAs are dysregulated in many cancers,
including PCa (Ayub, Kaul, & Ayub, 2015; Cannistraci, Di Pace, De Maria, & Bonci, 2014; Iorio
& Croce, 2009, 2012; Jones, Grizzle, Wang, & Yates, 2013; J. Lu et al., 2005; Luu et al., 2017;
MacFarlane & R. Murphy, 2010; Volinia et al., 2006; Wadhwa & Dumbre, 2016). MiRNAs can
play either the role of an oncogene when they target tumor suppressor genes and similarly as tumor
suppressors when they target oncogenes (Ayub et al., 2015; Cannistraci et al., 2014; Iorio & Croce,
2009, 2012; Jones et al., 2013; J. Lu et al., 2005; Luu et al., 2017; MacFarlane & R. Murphy, 2010;
Volinia et al., 2006; Wadhwa & Dumbre, 2016). Dysregulation of miRNAs signatures are not rare
but rather the rule of human cancer, including in PCa (Ayub et al., 2015; Cannistraci et al., 2014;
Iorio & Croce, 2009, 2012; Jones et al., 2013; J. Lu et al., 2005; Luu et al., 2017; MacFarlane &
R. Murphy, 2010; Volinia et al., 2006; Wadhwa & Dumbre, 2016). Thus, miRNA profiling has
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been a potent tool in identifying predictive miRNA signatures associated with the progression of
various cancers.
Based

on

miRNA

target

prediction

algorithm

tools,

TARGETSCAN

(http://www.targetscan.org/vert_72/) and miRDB (http://mirdb.org/), microRNA-4719 and
miRNA-6756-5p have been predicted to target the 3’ untranslated region (3’UTR) of IL-24 mRNA.
The present study aims to examine the expression, function, and molecular mechanisms of action
of potential miR-4719 and miR-6756-5p targeting of IL-24 in PCa progression in vitro. We
discovered that miR-4719 and miR-6756-5p are significantly overexpressed in CRPC cell lines
and particularly in African American men (AAM). Furthermore, IL-24 mRNA is decreased in all
PCa cells compared to normal prostate epithelial cells and we demonstrate that inhibition of miR4719 and miR-6756-5p increases IL-24 mRNA expression and significantly inhibits proliferation
and migration of CRPC cell lines.
These discoveries of novel miRNA-based targeting of IL-24 may improve understanding
of the molecular mechanisms in the development of CRPC and provide opportunities to explore
clinical applications of miR-4719 and miR-6756-5p in PCa. In addition, understanding the
mechanism in which IL-24 mRNA is stabilized could lead to the development of therapeutic
strategies that prolong IL-24 mRNA half-life enabling enhanced killing in tumor cells.

5.2 Results
5.2.1 MicroRNA-4719 and microRNA-6756-5p are significantly overexpressed in castrationresistant prostate cancer (CRPC) cells.
Based on the predicted results from two miRNA molecular target prediction algorithms,
TARGETSCAN and miRDB, we identified miR-4719 and miR-6756-5p as putative regulators of
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IL-24. These two microRNAs have never been studied in their regulation of IL-24 nor are there
any known reports on the roles of miR-4719 and miR-6756-5p in PCa. To investigate the
expression profiles, functional roles, and the molecular mechanisms of miR-4719 and miR-67565p as regulators of IL-24 in PCa biology, our work compares five different PCa cell lines modeling
different clinical characteristics of PCa: E006AA (indolent PCa), E006AA-hT (CRPC), DU-145
(CRPC), PC-3 (CRPC) to a non-tumorigenic prostate epithelial cell line, RWPE1 (Figure 13A).
qRT-PCR analysis shows that miR-4719 and miR-6756-5p are both significantly
overexpressed in all PCa cell lines (by >2-fold) compared to the normal prostate epithelial cell
line, RWPE-1 (Figure 13B-C). We observed that both miR-4719 (by at least 50%) and miR-67565p (>2 fold) are higher in CRPC cell lines compared to the indolent E006AA PCa cell line,
indicating their gain may be an early event in PCa progression (Figure 13A-B). Additionally, both
miR-4719 and miR-6756-5p expression were higher by (>3-fold) in the CRPC cell line E006AAhT compared to indolent cell line-E006AA (Figure 13A-B). Interestingly, miR-4719 and miR6756-5p is more significantly overexpressed in the CRPC of African American men (AAM)
(E006AA-hT) compared to aggressive PCa cell lines for Caucasian men (CM) (PC-3 and DU-145)
(Figure 13A-B).
To elucidate the functional roles of miR-4719 and miR-6756-5p expression in PCa,
commercially available synthetic oligonucleotide mimics of miR-4719 and miR-6756-5p (miR4719 mimic and miR-6756-5p mimic), synthetic oligonucleotide inhibitors of miR-4719 and miR6756-5p (miR-4719 inhibitor and miR-6756-5p inhibitor), or a synthetic non-targeting negative
control oligonucleotide (negative control) were transfected into the cells using Lipofectamine®
RNAiMAX. A dose-response experiment analyzed using qRT-PCR confirmed that the miR-4719
mimic and miR-6756-5p mimic increases endogenous expression of miR-4719 and miR-6756-5p,
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respectively, in a dose dependently fashion (Figure 13D-E). Similarly, the miR-4719 inhibitor and
miR-6756-5p inhibitor decreases endogenous miR-4719 and miR-6756-5p expression,
respectively, in a dose-dependent fashion (Figure 13F-G). A 50nM concentration of both the
mimics and inhibitors of miR-4719 and miR-6756-5p showed maximal specific effect on miR4719 and miR-6756-5p expression. Consequently, the 50nM dose was used to determine the roles
of miR-4719 and miR-6756-5p in regulating proliferation, and migration in CRPC cells.
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Figure 13. miR-4719 and miR-6756-5p are overexpressed in PCa cells and miR-4719 and miR-6756-5p
inhibitors and mimics affect miR-4719 and miR-6756-5p expression. A. Characterization of human cell lines used.
B-C. MiR-4719 and miR-6756-5p levels were measured in DU-145, PC-3, E006AA, E006AA-hT and RWPE-1 cell
lines by qRT-PCR. D-G. A dose-response test of the effect of a transiently transfected inhibitor and a mimic of miR4719 and miR-6756-5p on miR-4719 and miR-6756-5p expression was performed on and measured against a 50nM
non-targeting negative control. Data are presented as mean ± standard error of the mean (SEM). Statistical differences
were determined with one-way ANOVA; All the criterions for significance were set at P<0.05.
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5.2.2 IL-24 is downregulated in all prostate cancer cells and microRNA-4719 and microRNA6756-5p targets IL-24.
Using our panel of PCa cell lines, we discovered that IL-24 expression is downregulated
in aggressive CRPC cell lines compared to indolent PCa and the normal prostate epithelial cell
line, RWPE-1 (Figure 14A). Our data reveals that IL-24 expression is lower in the CRPC cell lines
PC-3, DU-145 and E006AA-hT cell lines when compared to its indolent counterpart, E006AA
(Figure 14A). This suggests that loss of IL-24 is associated with the progression to CRPC.
We next investigated if IL-24 may possibly be a molecular target of miR-4719 and miR6756-5p. Consequently, we assessed the effect of the microRNA mimics (overexpression) and
inhibitors (loss) of miR-4719 and miR-6756-5p on IL-24 mRNA expression in the RWPE-1,
E006AA-hT and PC-3 PCa cell lines (Figure 14B-G). qRT-PCR analysis show inhibition of miR4719 and miR-6756-5p significantly increases the expression of IL-24 in RWPE-1 cells
(~20%), E006AA-hT cells (~2.5 fold) and PC-3 cells (nearly 2-fold) compared to the negative
control. In contrast, overexpression of miR-4719 and miR-6756-5p reveals significant decrease
in IL-24 expression. Therefore, our findings indicate that miR-4719 and miR-6756-5p both
regulate IL-24 expression in PCa cells. Strategies to inhibit miR-4719 and miR-6756-5p
expression to increase IL-24 in may have therapeutic efficacy in PCa.
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Figure 14. miR-4719 and miR-6756-5p target IL-24. A. IL-24 mRNA expression was measured by qRT-PCR in
respective cell lines normalized to RWPE1. B-G. Effects of 50nM concentration of microRNA mimics and inhibitors
of miR-4719 and miR-6756-5p on IL-24 mRNA expression in the RWPE-1, PC-3 and the E006AA-hT PCa cell lines.
Data are presented as mean ± standard error of the mean. Statistical differences were determined with one-way
ANOVA. All the criterions for significance were set at P<0.05.
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5.2. 3 Loss of miR-4719 and miR-6756-5p significantly inhibits proliferation in CRPC cells.
We next compared the effects of inhibition and overexpression of miR-4719 and miR6756-5p on PCa cell proliferation. MTT assays revealed that inhibition of miR-4719 and miR6756-5p significantly decreases proliferation by 40%, while overexpression of miR-4719 and miR6756-5p increases proliferation by 50% in PC-3, E006AA and E006AA-hT PCa cell lines (Figure
15). Notably, we observed that overexpression of miR-4719 and miR-6756-5p increased
proliferation most in CRPC cells (PC-3 and E006AA-hT, >2-fold) compared to benign PCa cells
(E006AA, ~50%). Conversely, the inhibition of miR-4719 and miR-6756-5p decreased
proliferation most in CRPC cells (PC-3 and E006AA-hT, >50%) compared to benign PCa cells
(E006AA, ~35%). Inhibition of both miRNAs further decreased the proliferation of the CRPC
E006AA-hT cell line by an extra 40%, compared to indolent E006AA cell line. In contrast,
overexpression of miR-4719 and miR-6756-5p further increased the proliferation of the CRPC
E006AA-hT by an at least 50%, compared to the indolent E006AA.
Interestingly, overexpression of miR-4719 and miR-6756-5p led to an even higher
proliferative rate in the AAM CRPC cell line E006AA-hT by at least 30% compared to the
proliferative rate of the CM CRPC cell line, PC-3. Similarly, loss of miR-4719 and miR-6756-5p
led to a more reduced proliferative rate in the AAM CRPC cell line E006AA-hT by at least 20%
compared to the proliferative rate of the CM CRPC cell line, PC-3. Overall, the data demonstrates
that loss of miR-4719 and miR-6756-5p significantly inhibited cellular proliferation in CRPC.
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Figure 15. miR-4719 and miR-6756-5p loss significantly inhibits proliferation in CRPC. Transfection of a mimic
or inhibitor of miR-4719 and miR-6756-5p was performed. A-F. Effect of overexpression of miR-4719 and miR6756-5p and inhibition of miR-4719 and miR-6756-5p expression on proliferation of PCa cells assessed using the
MTT proliferation assay. Statistical differences were determined with one-way ANOVA. Data are presented as mean
+ standard error of the mean. All the criterions for significance were set at P<0.05.

5.2.4 Loss of miR-4719 and miR-6756-5p significantly inhibits migration in CRPC cells
Lastly, wound healing assays were performed to assess effect of the mimics and inhibitors
of miR-4719 and miR-6756-5p on migration of the CRPC PC-3 and E006AA-hT cell lines (Figure
16). Wound healing assays reveal that inhibition of miR-4719 and miR-6756-5p reduced migration
by approximately 50% compared to the negative control of the CM cell line, PC-3 (Figure 16A-
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B). We observed that inhibition of miR-4719 and miR-6756-5p more effectively reduced the
migration of CRPC E006AA-hT cells compared to the negative control, by ~60% and ~80%,
respectively (Figure 16 C-D). Strikingly, overexpression of miR-4719 and miR-6756-5p increased
the migratory capacity of both CRPC cell lines, in PC-3 by greater than 2-fold) and in E006AAhT by at least 3-fold (Figure 16A-D). Taken together, loss of miR-4719 and miR-6756-5p inhibited
proliferation and migration in CRPC cell lines.

Figure 16. miR-4719 and miR-6756-5p loss significantly inhibits migration in CRPC. Transfection of a mimic or
inhibitor of miR-4719 and miR-6756-5p was performed. A-D. Effect of overexpression of miR-4719 & miR-6756-5p
and inhibition of miR-4719 & miR-6756-5p expression on cell migration assessed using the wound healing assay.
Statistical differences were determined with one-way ANOVA. Data are presented as mean + standard error of the
mean. All the criterions for significance were set at P<0.05.
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5.3 Discussion
The chief obstacle in detecting and treating prostate cancer (PCa) is understanding the
molecular mechanisms involved in the progression of indolent tumors to lethal castrate-resistant
prostate cancer (CRPC) (Katsogiannou et al., 2015; Parnes et al., 2013; Wiklund, 2010). This is
essential for the discovery of robust prognostic markers that can identify patients with the greatest
risk of relapse and optimize management strategies to control PCa progression (Katsogiannou et
al., 2015; Obinata et al., 2017; Parnes et al., 2013; Wiklund, 2010). Thus, in cancer biology,
microRNAs (miRNAs) studies have become important for the discovery of miRNA-based
diagnostic, prognostic and theranostic biomarkers (Ayub et al., 2015; Cannistraci et al., 2014; Iorio
& Croce, 2009, 2012; Jones et al., 2013; J. Lu et al., 2005; Luu et al., 2017; MacFarlane & R.
Murphy, 2010; Volinia et al., 2006; Wadhwa & Dumbre, 2016). Changes in miRNA levels can
provide critical information on a disease’s molecular signature status through the course of
treatment and recurrence without the need for a biopsy.
Here, we have presented the rationale for investigating the novel roles of microRNA-4719
and microRNA-6756-5p in respect to Interleukin-24 (IL-24) in PCa. The miRNA mechanisms
regulating IL-24 mRNA or protein levels have not been fully delineated in the progression of PCa.
When overexpressed, IL-24 kills PCa cells through several pathways. IL-24 can cause
mitochondrial dysfunction, reactive oxygen species production, and calcium mobilization leading
to apoptosis in PCa cell lines (Do et al., 2013). IL-24 can also downregulate anti-apoptotic proteins
such as Bcl-2 and Bcl-xL and produce of tumor-suppressing ceramides leading to endoplasmic
reticulum stress, autophagy, and apoptosis in PCa (Bhutia et al., 2010; Do et al., 2013; Irina V
Lebedeva et al., 2003; Sauane et al., 2008, 2010; Tian et al., 2012). In mouse PCa xenografts, IL24 decreases the levels of secreted soluble clusterin (sCLU) protein, which is linked to resistance
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to chemotherapy and radiation and hormone therapies, leading to reduced tumor growth and
angiogenesis (Bhutia, Das, Kegelman, et al., 2013). Supporting these studies, IL-24 has been found
to reduce factors of stemness such as migration, invasion, colony formation and inhibit the
expression of Sex Determining Region Y-Box 2 (SOX2) transcription factor, CD44 cell-surface
glycoprotein and ATP Binding Cassette Subfamily G Member 2 (ABCG2) compared to other
cytokines, IL-3, IL-6 and IL-11 in PCa cells (D.-D. Yu et al., 2015). In combination with ionizing
radiation, IL-24 is also able to induce apoptosis in PCa cells overexpressing Bcl-2 and Bcl-xL
proteins that would normally exhibit resistance to IL-24 treatment alone (Z. Z. Su et al., 2006).
Combination treatment of Sabutoclax, an inhibitor of prosurvival myeloid cell leukemia protein,
with IL-24 also sensitizes PCa tumors to IL-24-mediated apoptosis (Dash et al., 2011).
In terms of IL-24 expression regulation in cancer cells, two studies have demonstrated that
IL-24 mRNA regulation occurs at the 3’ untranslated region (3’UTR) via activation of p38 MAPK
(Otkjaer et al., 2010; Sauane et al., 2008). In addition, miRNA-205, which is silenced in human
PCa cell lines, has been shown to directly target the Il-24 promoter to induce gene expression in
human PCa and oral cancer cells (Majid et al., 2010; Otkjaer et al., 2010). Furthermore, IL-24
mRNA has been reported to have a relatively short half-life (~20min) due to the presence of three
AU-rich elements (ARE-sequences), which are targets for RNA-binding proteins leading to
mRNA destabilization and degradation (Otkjaer et al., 2010).
In this study, we describe for the first time a potential IL-24/miR-4719 and IL-24/miR6756-5p regulatory pathway in PCa which has important clinical implications as miRNAs possess
several key features that make them attractive PCa biomarkers (Figure 17). We discovered that the
expression of miR-4719 and miR-6756-5p is significantly overexpressed in PCa cells (Figure 13).
Furthermore, both microRNAs demonstrate differential expression between indolent and CRPC.
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We also demonstrate expression of miR-4719 and miR-6756-5p in PCa cells significantly
increases cancer cell proliferation and migration (Figures 15-16). As predicted, we show that
miRNA-4719 and miRNA-6756-5p inhibitors also increase the expression of IL-24 mRNA and
significantly inhibit PCa and CRPC proliferation and migration. (Figures 14-16). As miRNAs are
known to be involved in the destabilization of mRNA thus, reducing expression of proteins such
as tumor suppressors, and we show that miRNA-4719 and miRNA-6756-5p decreases IL-24
expression, it is possible that miRNA-4719 and miRNA-6756-5p are involved in posttranscriptional modification of IL-24 by destabilizing IL-24 3’UTR, thus, shortening IL-24’s halflife.
To increase IL-24’s specific killing effect, miRNA-4719 and miRNA-6756-5p
oligonucleotide inhibitors could be used in conjunction with IL-24 treatment to increase
endogenous production of IL-24 and thus, increase apoptosis in cancer cells. It has been shown
that miRNAs can simultaneously modulate several cancer-relevant gene pathways and can be
exploited to increase the sensitivity of tumor cells to conventional anticancer agents (Calin et al.,
2004; Cannistraci et al., 2014; Iorio & Croce, 2009; J. Lu et al., 2005; Rupaimoole & Slack, 2017;
Watahiki et al., 2011). Due to the potential to be one-hit multi-target therapeutic agents against
PCa, miRNAs are interesting drug candidates (Cannistraci et al., 2014; Iorio & Croce, 2012;
Karlou, Tzelepi, & Efstathiou, 2010; Rupaimoole & Slack, 2017). Furthermore, our functional
experiments clearly demonstrate a mechanism by which miR-4719 and miR-6756-5p regulate key
cellular processes that are dysregulated in the development and progression of PCa thus, strategies
to reduce miR-4719 and miR-6756-5p in PCa may have therapeutic value in CRPC. In terms of
diagnostic significance, the increased levels of miR-4719 and miR-6756-5p expression in CRPC
cells compared to normal prostate epithelial cells indicates that both miRNAs may potentially
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serve as biomarkers to risk stratify PCa. Further studies using clinical samples are needed to test
the potential of miR-4719 and miR-6756-5p as biomarkers, however. Interestingly, a recent study
showed that circulating miRNA-6756-5p along with miR-1246, and miR-8073 were successfully
used as biomarkers to detect breast cancer with a 97.1% accuracy (Cui et al., 2018). Along with
our work, this suggests that miRNA-6756-5p could be a useful biomarker for detecting various
cancer cell types.
Along with studying how miRNA-4719 and miRNA-6756-5p affects IL-24 expression, we
also investigated the impact of racial disparity in PCa since African American men (AAM) have a
2-fold higher chance of getting aggressive PCa and disparities in tumor aggressiveness remain
after controlling for social determinants (Chung et al., 2014; Evans, Metcalfe, Ibrahim, Persad, &
Ben-Shlomo, 2008; Hoffman et al., 2001; Jones et al., 2013; Koochekpour et al., 2004, 2014;
Powell, Bock, Ruterbusch, & Sakr, 2010; Presley et al., 2013). To address this high mortality,
effective early detection and therapeutic strategies are needed (Chung et al., 2014; Evans et al.,
2008; Hoffman et al., 2001; Jones et al., 2013; Koochekpour et al., 2004, 2014; Powell et al., 2010;
Presley et al., 2013). In this regard, we discovered that miR-4719 and miR-6756-5p seem to
directly correlate with aggressive PCa cell lines and is differentially expressed between Caucasian
men (CM) and AAM cell lines tested in our study (Figure 13B-C). Moreover, miR-4719 and miR6756-5p significantly inhibited IL-24 expression more potently in the AAM cell line compared to
the CM cell lines (Figure 14D-G). The data suggests that miR-4719 and miR-6756-5p may play a
role in explaining the disproportionately increased aggressiveness of PCA in AAM. A limitation
of our study is the small sample size. The problem lies in the fact that the majority of established
PCa cell lines are derived from Caucasian men (CM) patients. To date, there are only four authentic
and spontaneously transformed African American men (AAM) PCa cell lines. These include
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E006AA (primary PCa cell line), E006AA-hT (a subline of E006AA), MDA-PCa2a and MDAPCa2b (Powell et al., 2010; Presley et al., 2013). In our study, we were able to compare these two
proven cell lines, (E006AA and E006AA-hT) derived from AAM with different clinical
characteristics which are clinically relevant and compared them against three cell lines from CM
with different clinical characteristics (RWPE-1, PC-3, and DU-145). In future studies, we intend
to investigate miR-4719 and miR-6756-5p in PCa tissue samples derived from both AAM and
CM. The discovery of a miRNA biomarker that can display differential expression between races
is of great significance for the development and optimization of miR-4719 and miR-6756-5p-based
therapeutic strategies for personalized treatment.
In conclusion, this is the first report to show miR-4719 and miR-6756-5p as potential
regulators of IL-24 mRNA expression and as candidate biomarkers for risk stratification of PCa,
as well as help explain the racial disparity of PCa. Loss of miR-4719 and miR-6756-5p
significantly inhibited proliferation and migration in CRPC cell lines via targeting of IL-24.
Consequently, these in vitro studies also demonstrate the potential of miR-4719 and miR-6756-5p
serving as both diagnostic biomarkers and as therapeutics for CRPC
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Figure 17. Hypothesized pathway of microRNA-4719 and microRNA-6756-5p targeting IL-24 to regulate
cellular proliferation and migration in CRPC cell lines. miR-4719 and miR-6756-5p bind to IL-24 3’UTR leading
to destabilization of IL-2 mRNA, a decrease in IL-24 protein production, and increase in CRPC cell proliferation and
migration.
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Chapter 6: Summary and Discussion
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6.1 Interleukin-24 is an Inhibitor of Translation Initiation in Cancer Cells.
Supra-physiologic activation and/or overexpression of translation initiation factors are
involved in the initiation and progression of cancer in animal models as well as a subset of human
cancers whereby they correlate with cancer aggressiveness and a poor prognosis (Bhat et al., 2015;
Qin, Jiang, & Zhang, 2016; Rosenwald et al., 2008; S. Wang et al., 1999). Two rate-limiting
translation initiation complexes, the ternary complex (TC) and the eIF4F complex are regulated
by eIF2α phosphorylation and mammalian target of rapamycin/4E-BP (mTOR/4E-BP) activation,
respectively. Overexpression of eIF2α is correlated with very aggressive lymphomas suggesting
that its dysregulation contributes to cancer (Rosenwald et al., 2008; S. Wang et al., 1999). Previous
studies show that IL-24 activates ER stress and phosphorylates eIF2α in lung and prostate cancer
cells (Pataer et al., 2002; Sauane et al., 2006, 2008). IL-24 also increases the expression of
downstream markers of TC availability such as binding immunoglobulin protein (BiP) and C/EBP
homologous protein (CHOP) (Do et al., 2013; Gupta et al., 2006; Harding et al., 2000). Thus, we
hypothesized that IL-24 activates eIF2α and prevents the formation of TC to stop translation
initiation, leading to the induction of apoptosis in cancer cell lines.
First, we show that multiple cell line (breast cancer, cervical cancer, melanoma and
squamous cell carcinoma) are prone to eIF2α phosphorylation at serine 51 and cell death after
treatment with a non-replicating adenoviral vector expressing the IL-24 gene (Ad.IL-24) (Figure
1). These results support previous reports showing that sustained phosphorylation of eIF2α inhibits
cell growth (B. H. Aktas et al., 2013; H Aktas et al., 1998; Denoyelle et al., 2012). To confirm if
IL-24’s inhibition of cancer cell growth depends on the phosphorylation of eIF2α, genetically
engineered squamous cell carcinoma KLN cells stably expressing the eIF2α wildtype protein
(eIF2α-WT) or constitutively active non-phosphorylatable eIF2α mutant protein (eIF2α-S51A),
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were treated with Ad. IL-24 with increasing concentrations. We found that these genetically
engineered cancers cells containing non-phosphorylatable eIF2α-S51A did not respond to
treatment with Ad.IL-24 in contrast to eIF2α-WT, which were killed by apoptosis after Ad.IL-24
treatment (Figure 2A-D). IL-24 also reduced global protein synthesis by nearly 50% in eIF2α-WT
cells supporting the hypothesis that IL-24 inhibits translation (Figure 1D). The key, however, was
whether IL-24’s regulation of translation was dependent on its inhibition of TC.
To test the hypothesis that IL-24-mediated phosphorylation of eIF2α leads to TC
formation, a dual-luciferase cell-based reporter assay in which the reported expression of the 5’
UTR of ATF-4 is dependent on TC formation, was used (B. H. Aktas et al., 2013). Since the
formation of TC is a rate-limiting step in translation initiation, it affects the expression of specific
mRNAs of oncogenic proteins and transcriptional regulators such as ATF-4, which is more
efficient under ER stress and when TC is limited (Dever, 2002; Harding et al., 2000; Vattem &
Wek, 2004). This is the basis of the cell reporter assay whereby the expression of the 5’UTR of
ATF-4 correspond inversely to levels of TC formation (B. H. Aktas et al., 2013; Mingli Yang, Ito,
& May, 2003). As expected, when treated with increasing concentrations of Ad.IL-24, there was
a proportional increase in the expression of the ATF-4 reporter, as measured by a high F/R ratio,
suggesting that IL-24 depletes TC availability (Figure 3B). This correlates with the preferential
downregulation of oncogenic proteins such as Bcl-2, c-MYC, survivin, cyclin E, and cyclin D1 at
the translational level (Figure 4A). The 5’UTR regions of these corresponding oncogenic mRNAs
are known to have complex structural motifs making their translation tightly regulated (H Aktas
et al., 1998; Bhat et al., 2015; Robichaud, Sonenberg, Ruggero, & Schneider, 2018; Shahid,
Bugaut, & Balasubramanian, 2010). Thus, when regulation of translation initiation is lost due to
aberrant signaling and overexpression of specific translation initiation factors, malignant
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transformation can occur leading to the development of cancer. By inhibiting TC formation, IL24 can selectively decrease the translation of these oncogenic mRNAs. To further assess the
hypothesis that IL-24 impedes the formation of TC, Western blot analysis was done to measure a
downstream marker of TC formation such as CHOP after Ad.IL-24 treatment. IL-24 did indeed
increase the protein level of CHOP demonstrating its role in inhibiting TC formation (Figure 3D).
Therapeutics that attack translation, specifically the rate-limiting processes in the initiation
stage like TC formation and eIF4F assembly are essential to killing cancer cells because they can
disable the core machinery necessary for cancer cells to grow and proliferate (Bjornsti &
Houghton, 2004; Clemens & Bommer, 1999; Ruggero, 2013; Silvera et al., 2010). Pursuing
translation inhibition may be a more effective approach that can be used against different cancer
cell types that exploit a variety of aberrant pathways based on their genetic profiles. Since IL-24
exhibits a broad anti-cancer effect in many tumor cell types, its widespread killing effect could be
attributed to inhibition of translation as a downstream pathway of ER stress. Future studies
exploring the synergistic effects of IL-24 and other global protein synthesis inhibitors could prove
useful as potential anti-cancer treatments against tumors that exhibit intra-tumor heterogeneity
whereby subsets of cells in the same tumor can have varied morphological, genetic, metabolic, or
metastatic characteristics (Bhat et al., 2015). Table 1 summarizes the current cancer therapeutics
that target rate-limiting steps of protein translation initiation that have been tested in vitro, in vivo
or in clinical trials.
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Inhibitors of Translation Machinery
Inhibitor

Salubrinal

BTdCPU (N,N′diarylurea)
NSC119889
NSC119893

Mechanism

Stage of Development

Inhibition of eIF2α
dephosphorylation

• Displays synthetic lethality in combination with proteasome
inhibitors (Schewe & Aguirre-Ghiso, 2009)
• Increases doxorubicin sensitivity in vitro (Jeon et al., 2016)
• Works synergistically with VCP inhibitors in ovarian cancer
(Bastola, Neums, Schoenen, & Chien, 2016)
• Phase II clinical trial in combination with carfilzomib
(NCT01775553)

Activation of HRI
and eIF2α
phosphorylation
Prevents tRNA eIF2 interaction
Met
i

• Effective in vivo xenograft models (L. Chen et al., 2015; T.
Chen et al., 2011)
• Inhibition of global translation in vitro (Robert et al., 2006)

4E-antisense
oligonucleotide

Reduction of
eIF4E expression

• Inhibits tumor growth and angiogenesis with low toxicity
in mice (A De Benedetti, Joshi-Barve, Rinker-Schaeffer,
& Rhoads, 1991; Graff et al., 2007, 2009)
• Reduces eIF4E protein levels in human tumors (Hong et
al., 2011)
• Phase I/II clinical trials in combination with docetaxel and
prednisone in non-small-cell lung cancer and CRPC
(NCT01234038 and NCT01234025)

Cap analogues
including the prodrug 4Ei-1

Inhibition of
eIF4E binding to
5’cap

• Delivery in vivo was recently made possible using viruslike particles (Zochowska et al., 2015)
• 4Ei-1 pro-drug blocks cap-dependent translation and EMT
in zebrafish (Ghosh et al., 2009)

4EGI-1
4E1RCat
4E2RCat

Inhibition of
eIF4E–eIF4G
interaction

• 4EGI-1 induces apoptosis in cancer cell lines and inhibits
melanoma and breast cancer xenografts (L. Chen et al.,
2015; De et al., 2018; Moerke et al., 2007)
• 4E1RCat/4E2RCat reverse drug resistance in lymphoma
model (R. Cencic et al., 2011)

Inhibition of
eIF4A helicase
activity

• Hippuristanol shows pre-clinical efficacy in leukemia
mouse model and resensitizes tumors to DNA-damaging
agents in lymphoma (R. Cencic et al., 2013; Tsumuraya et
al., 2011)
• Pateamine A derivatives display single-agent activity in
xenograft models (Low et al., 2014; Marsh et al., 2009)
• Silvestrol induces apoptosis and tumor regression in
mouse models and improves the potency of doxorubicin
in lymphoma model (Bordeleau et al., 2008; R. Cencic et
al., 2013; Regina Cencic et al., 2009)

Hippuristanol
Pateamine A
Silvestrol

Table 1: Inhibitors of translational machinery in cancer. Modified from (Bhat et al., 2015) Abbreviations: CRPC,
castration resistant prostate cancer; eIF, eukaryotic translation initiation factor; EMT, epithelial-to-mesenchymal
transition; HRI, heme-regulated inhibitor; tRNAiMet, initiator methionyl tRNA; VCP, valosin containing protein.
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6.2 Interleukin-24 Activates ER Stress and Protein Kinase A in Breast Cancer Cells
ER stress-induced apoptosis is primarily regulated through the extent of eIF2α
phosphorylation and ATF-4 activation. Researchers have shown that after treating human liver
carcinoma cells with palmitate, a saturated fatty acid involved in ER stress, protein kinase A (PKA)
induces apoptosis by increasing ATF-4 expression (Cho et al., 2013). After the delayed activation
of PKA, ATF-4 interacts with cyclic-AMP-responsive element-binding protein 1 (CREB1), a
downstream target of PKA, and binds to the Atf-4 promoter leading to a sustained level of ATF-4
protein expression. It is suggested that this feedback loop, involving activated PKA, is necessary
for the induction of apoptosis via ER stress and CREB1 phosphorylation. This loop occurs after
palmitate induces the PKR-eIF2α-ATF-4 pathway to promote continual phosphorylation of eIF2α
by PERK, initiating the ER stress-induced apoptosis.
Like palmitate, IL-24 increases the phosphorylation eIF2α, which we suggest may be one
of the first events to induce apoptosis via translation inhibition (Persaud et al., 2017). Due to the
effect of PKA on ER stress and its role as a key growth regulator, we hypothesized that PKA is an
upstream mediator of IL-24’s killing activity and may regulate several of IL-24’s downstream
signaling pathways including ATF-4 activation. We show for the first time that PKA activation is
required for IL-24-induced cell death in a variety of breast cancer cell lines (MCF-7, MDA-MB231, MDA-MB-157, T47D) and this event increases the phosphorylation of ATF-4 at serine 245
(Figure 7). We found that inhibiting PKA activity using H-89, a small molecule drug blocking the
ATP binding site within the catalytic subunits of PKA and/or PKI, a peptide sequence binding to
the catalytic subunit of PKA, decreased IL-24-mediated apoptosis indicating that PKA is involved
in IL-24’s killing effect (Figure 9A-B). Additional assays other than Annexin V analysis could
employed to confirm the activation of apoptosis as Annexin V analysis is time-dependent and the
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phosphotidylserine lipid that Annexin V binds to appears at an early stage of apoptosis. To confirm
apoptosis has occurred, caspase-3 analysis and the terminal dUTP nick end-labeling (TUNEL)
technique can be used.
PKA is a serine/threonine kinase that phosphorylates many proteins in response to
fluctuations in cyclic adenosine monophosphate (cAMP) levels. To examine if IL-24
overexpression activates PKA in cancer cells, the levels of phospho-PKA substrates were
measured by Western blot. As expected, Ad.IL-24 treatment increased the phosphorylation of PKA
substrates in a dose-dependent manner (Figure 8A). This effect was reversed in the presence of H89. IL-24-mediated activation of PKA was distinguished from possible changes of total PKA
protein due to the unchanged levels of PKA catalytic alpha subunit (PKA-C-α) (Figure 8C). In
addition, since PKA activity is generally dependent on cAMP, we performed an assay to
quantitatively measure cAMP levels after Ad.IL-24 treatment in MCF-7 cells. We found that IL24 did indeed increase cAMP levels in a dose-dependent manner supporting the hypothesis that
IL-24 as an activator of PKA (Figure 8B). This effect would need to be tested in non-cancerous
cells as chronically elevated cAMP levels may be detrimental to other tissue types (Gold, Gonen,
& Scott, 2013). Despite this IL-24 has been shown to not have a toxic effect on normal cells, which
suggests that if IL-24 does indeed increase cAMP in normal cells, there may be an unknown
mechanism that does not result in toxic signaling. It would be helpful to study whether Ad.IL-24
influences the activation of G protein-coupled receptor (GPCR) in the plasma membrane, which
is known to produce cAMP as a secondary messenger. Other studies have indicated that
internalization of GPCRs, which normally inhibits secondary messenger production, in fact,
potentiates cAMP production and can promote PKA activation depending on GPCR localization
(Calebiro et al., 2009). Sigma-1 receptor (Sig1R), which is found in the plasma membrane and
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also co-localizes with IL-24 to induce ER stress, could be a receptor that interaction with GPCR
to promote IL-24’s activation of cAMP (Do et al., 2013). Further experiments are needed to test
this hypothesis.
Since PKA has a prominent role in integrating signals from multiple cellular stimuli, we
hypothesized that IL-24 activates PKA to mediate its downstream signaling effects involving
mediators such as p38 MAPK, which is known to regulate IL-24 expression (Otkjaer et al., 2010;
Sarkar et al., 2002). We found that H-89 abrogated IL-24-mediated phosphorylation of p38 MAPK
at threonine180/tyrosine182 as detected with Western blot analysis indicating that PKA is involved
in IL-24-mediated activation of p38 MAPK (Figure 9D). Since it is known that activated p38
MAPK is involved in stabilizing IL-24 mRNA and upregulating protein expression and we
demonstrate that PKA is involved in IL-24-mediated p38 MAPK activation, it is possible that PKA
plays a role in increasing cellular levels of IL-24 protein, however, we did not definitively
determine this in our studies.
In this work, we found that the increased phosphorylation levels of ATF-4 at serine 245
and total ATF-4 in respect to IL-24-mediated PKA activation further characterizes PKA as an
effector of ER stress in cancer cells treated with IL-24 (Figure 6). Phosphorylation of ATF-4 at
the serine residue 245 (phospho-Ser245 ATF-4) by the serine/threonine kinase, RSK2, protects
ATF-4 from ubiquitination in colorectal cancer cells (Hao et al., 2016). It is possible that the
protective role of this phosphorylated residue stabilizes ATF-4 allowing for a positive feedback
loop resulting in the interaction and binding of ATF-4:CREB1 to the Atf-4 promoter. This in turn
could stabilize ATF-4 production and thus, cause ER stress-induced apoptosis as suggested in Cho
et al. (Cho et al., 2013).
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We also demonstrate that phosphorylation and nuclear import of tumor suppressor TP53
occurs downstream of IL-24-mediated PKA activation (Figure 10). In this study, IL-24 activates
the phosphorylation of TP53 at the serine 15 residue. This phosphorylation event is well known to
be involved in stabilizing TP53, increasing transcriptional activation, cell cycle arrest, and
apoptosis, and even cellular senescence in cancer cells (Fiscella et al., 1993; D.-C. Li et al., 2006;
S.-Y. Shieh, Ikeda, Taya, & Prives, 1997; Tibbetts et al., 2008; Tonnessen-Murray, Lozano, &
Jackson, 2017; Unger et al., 1999; Webley et al., 2000). We show that IL-24 is unable to activate
TP53 at the same intensity when PKA is inhibited demonstrating the potential role of PKA in
regulating TP53 (Figure 10B). Though we know that IL-24 can induce apoptosis independent of
TP53 as suggested by our results where Ad.IL-24 induces p53-independent apoptosis in different
p53 status breast cancer cells (Figure 9A-B), future experiments exploring whether IL-24 activates
phospho-Ser15 TP53 to induce cellular senescence could illuminate a new mechanism of action
of IL-24 as a tumor suppressor. Targeting cellular senescence in cancer cells, or tumor senescence,
has been suggested as an alternative approach to controlling growth of cancer cells that do not
have intact apoptotic machinery and therefore are desensitized to death signals (Kahlem, Dörken,
& Schmitt, 2004). Interestingly, IL-24 has been found to induce cellular senescence in human
hepatic stellate cells, a model for liver fibrosis (Jamhiri et al., 2018). Whether IL-24 can induce
tumor senescence has not been studied yet.
Like ER stress, PKA activity has been shown to be pro-apoptotic in cancer cells (Table 2).
The involvement of PKA in cancer cell apoptosis has been studied in human gastric epithelial
carcinoma cells, in which allicin, a major component of garlic, is able to induce caspaseindependent apoptosis when PKA is not inhibited by H-89 (Park et al., 2005). A study examining
the beta 2 adrenergic receptor (ß2AR) agonist, ARA-211 (commercially known as Pirbuterol),
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which causes apoptosis and human tumor regression in animal models, demonstrated that ARA211 stimulation blocked malignant transformation contingent on cAMP-dependent activation of
PKA in a variety of cancers (Carie & Sebti, 2007). Others have shown that the activation of the
cAMP-PKA pathway by ß2AR agonist, isoprenaline, or forskolin decreases breast cancer cell
migration (Clarysse et al., 2014). An in vivo study also demonstrated that transforming growth
factor beta (TGFß) activates PKA to promote apoptosis and decreases metastasis in colon cancer
cells (Chowdhury et al., 2011). Leptin, a hormone that is linked to breast cancer, has also been
shown to intensify the anti-proliferative effect of cAMP elevating agents such as 8Bromoadenosine 3',5'-cyclic adenosine monophosphate (8-Br-cAMP), forskolin, and 3-isobutyl1-methylxanthine (IBMX) in MDA-MB- 231 breast cancer cells (Naviglio et al., 2009). When
studied in human breast cancer cell line Hs578T, researchers found that PKA was also involved in
increased ceramide levels and pro-apoptotic effects of insulin-like growth factor-binding protein3 (Perks, Burrows, & Holly, 2010).
In addition, here we show an undocumented role of PKA in regulating IL-24-induced cell
death, whereby IL-24 upregulates apoptotic factors of the Fas/FasL signaling pathway and death
receptor 4 suggesting the activation of extrinsic apoptosis (Figure 11). The protein levels of key
molecules such as DR4, Fas, FasL, FADD, were studied after Ad.IL-24 and/or PKA inhibitor
treatment to determine whether IL-24 requires PKA to activate these apoptotic pathways.
Interestingly, another study suggested that PKA is needed to induce the FasL–Fas–FADD–
caspase-8 pathway after phosphorylation of Par-4 at threonine 155 (phospho-Thr155 Par-4) in
lung, prostate, and breast cancer cell lines (Gurumurthy, Goswami, Vasudevan, & Rangnekar,
2005). This is based on earlier studies revealing that the induction of the Fas death pathway is
dependent on the nuclear localization of the selective for apoptosis induction in cancer cells (SAC)
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domain of phospho-Thr155 Par-4 and inhibition of the NF-kappaB pro-survival pathway (ElGuendy, Zhao, Burikhanov, Gurumurthy, & Rangnekar, 2003). Though, it is not shown directly
in this work, Par-4 may be the downstream factor that connects IL-24-mediated PKA activation to
the stimulation of the Fas pathway resulting in extrinsic apoptosis in cancer cells. The researchers
of these studies also reported higher PKA enzymatic activity (5- to 82-fold) in various cancer cell
lines compared to non-transformed counterparts, suggesting that phospho-Thr155 Par-4 can
selectively induce apoptosis due to the relatively higher levels of PKA activity present in cancer
cells. It is possible that IL-24 could be exploiting this high level of PKA activation to selectively
drive cancer cell towards apoptosis by simultaneously potentiating the effect of multiple apoptotic
signaling pathways via ER stress and/or inhibition of translation initiation.
Based on the described literature and the results presented here, PKA seems to be a proapoptotic mediator in IL-24’s activation of ER-stress and resulting apoptotic signaling pathways
involving ATF-4, p38 MAPK, TP53, and Fas/FasL signaling. To further confirm that PKA
inhibition downregulates IL-24-mediated activation of these pathways, additional PKA inhibitors
other than H-89 can be employed as it been shown that H-89 can also inhibit other kinases
(Lochner & Moolman, 2006). These insights could have important therapeutic implications
especially in precision therapy whereby patients with tumors containing wildtype PKA and the
required proteins for IL-24-mediated apoptosis would benefit from IL-24 treatment. In addition,
the various molecules and agents summarized in Table 2 that utilize the cAMP-PKA pathway
could be studied in combination with IL-24 to explore synergistic apoptotic activities in different
cancer cell types and not only breast cancer, which this work has been limited to. Overall, these
studies uncover a new mechanism in which IL-24 induces apoptosis through PKA activation,
which is relevant to IL-24’s broad therapeutic potential against cancer cells.
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Agents Activating cAMP-PKA-mediated Apoptosis
Agent

Mechanism
AIF release from
mitochondria

Allicin

Stage of Development
• Activates caspase-independent apoptosis in human epithelial
carcinoma (Park et al., 2005)
• Phase II clinical trial in follicular lymphoma stage III/IV
(NCT00455416)

ß2AR agonist

• Pirbuterol causes apoptosis in vitro and breast cancer xenografts in
mice (Carie & Sebti, 2007)
• Isoprenaline inhibits SK3/Orai complex decreasing breast cancer cell
migration (Clarysse et al., 2014)
• Salbutamol and isoprenaline reduce tumor growth in breast cancer
mice xenografts (Pérez Piñero, Bruzzone, Sarappa, Castillo, & Lüthy,
2012)

Multiple

• Inhibits SK3/Orai complex to decrease breast cancer cell migration
(Clarysse et al., 2014)
• Inhibits both leptin-induced proliferation and migration in breast
cancer cell lines (Naviglio et al., 2009, 2010)

8-Br-cAMP
IBMX

Multiple

• 8-Br-cAMP induces extrinsic apoptosis in lung, prostate, and breast
cancer cell lines (Gurumurthy et al., 2005)
• 8-Br-cAMP and IBMX inhibits leptin-induced proliferation and
migration in breast cancer cell lines (Naviglio et al., 2009, 2010)

TGFß

Proteasomal
degradation of
XIAP

• Promote apoptosis and decreases metastasis in colon cancer in vitro
(Chowdhury et al., 2011)

IGFBP-3

Rho
phosphorylation

• Increases ceramide levels and apoptosis in breast cancer cell lines
(Perks et al., 2010)

Pirbuterol
Isoprenaline
Salbutamol

Forskolin

Table 2: Activators of cAMP-PKA in in cancer. Abbreviations: 8-Br-cAMP, 8-Bromoadenosine 3',5'-cyclic
adenosine monophosphate AIF, apoptosis-inducing factor; ß2AR, beta 2 adrenergic receptor; cAMP; 3',5'-adenosine
monophosphate; IBMX, 3-isobutyl-1-methylxanthine; IGFBP-3, insulin-like growth factor-binding protein-3; Orai
1, calcium release-activated calcium channel protein 1; SK3, small conductance calcium-activated potassium channel
3; XIAP, X-linked inhibitor of apoptosis

6.3 IL-24 mRNA is regulated by microRNA-4719 and microRNA-6756-5p
The past 20 years of research on IL-24 has established IL-24 as a unique cytokine
possessing specific anti-cancer properties. Although the signaling pathways triggered by IL-24
have been the subject of intensive studies, we are only beginning to understand the
interconnections of IL-24’s vast molecular network. Few of these studies, however, have examined
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the regulators and molecular mechanisms underlying IL-24 mRNA and protein expression in
cancer cells. Section 1.3 of this work reviews the current literature describing specific proteins and
microRNAs that contribute to the stabilization of IL-24 mRNA and increased levels of IL-24
protein. Understanding the methods in which IL-24 expression can be upregulated has implications
in cancer treatment and other diseases.
To further characterize the possible methods in which IL-24 expression is affected, we used
miRNA target prediction algorithm tools to identify miR-4719 and miR-6756-5p as putative
regulators of IL-24. Since specific microRNAs (miRNAs) are dysregulated in prostate cancer
(PCa) (Ayub et al., 2015; Cannistraci et al., 2014; Iorio & Croce, 2009, 2012; Jones et al., 2013;
J. Lu et al., 2005; Luu et al., 2017; MacFarlane & R. Murphy, 2010; Volinia et al., 2006; Wadhwa
& Dumbre, 2016), we hypothesized that miR-4719 and miR-6756-5p expression are altered in PCa
and this differential expression destabilizes IL-24 mRNA. After qRT-PCR analysis, we found that
miR-4719 and miR-6756-5p are overexpressed in PCa cells compared to normal prostate epithelial
cells (Figure 13). Compared to the indolent PCa and normal prostate epithelial cells, miR-4719
and miR-6756-5p are significantly overexpressed in CRPC cell lines suggesting their gain may be
an early event in PCa progression. To determine whether miR-4719 and miR-6756-5p affects IL24 mRNA expression, qRT-PCR was performed after miR-4719 and miR-6756-5p mimic
treatment in E006A-hT and PC3 cancer cells. Our analysis shows miR-4719 and miR-6756-5p
overexpression significantly decreases the expression of IL-24 in PCa cells compared to the
negative control mimic of scrambled miRNA (Figure 14). We did not, however, determine whether
miR-4719 and miR-6756-5p physically bind to the 3’UTR of the IL-24 mRNA. In order to do this,
miRNA biotinylation pull-down assays could be performed to specify which mRNAs are bound
by miR-4719 and miR-6756-5p. In addition, immunoprecipitation of the RNA-induced silencing
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complex (RISC), which is involved in aiding miRNA interference at the 3’UTR, along with deep
sequencing could identify target mRNAs.
Based on the above results we hypothesized that inhibitors of miR-4719 and miR-6756-5p
induces killing and prevent migration. To functionally determine if miR-4719 and miR-6756-5p
significantly inhibits IL-24-mediated killing or promotes migration in cancer cells, miR-4719 and
miR-6756-5p oligonucleotide mimics and inhibitor oligonucleotides were introduced to PC3,
E006AA and E006AA-hT PCa cells. We found that inhibiting the expression of miR-4719 and
miR-6756-5p significantly increased IL-24 expression and inhibits cell proliferation and migration
of CRPC cell lines indicating that these miRNAs may allow cancer cells to migrate and evade
apoptosis (Figures 15-16). We also found that, miR-4719 and miR-6756-5p are significantly
overexpressed in the CRPC of African American males (E006AA-hT) compared to CRPC of
Caucasian males (PC-3 and DU-145), indicating that miR-4719 and miR-6756-5p may also play
a role in racial disparity via targeting of IL-24 (Figure 13 B-C). This is the first time in which lack
of IL-24 expression may be linked to racial disparity in cancer, however, additional studies need
to be done to fully evaluate this assertion.
Moreover, while our study tested these miRNAs in PCa, it is known that IL-24 is generally
downregulated melanoma cells and more recently, found to be downregulated in patients with
Burkitt lymphoma and B cell lymphoma, which researchers suggest is a predictor for poor
prognosis (Allen et al., 2004; Ma et al., 2018a, 2018b). Further studies looking at the expression
of miR-4719 and miR-6756-5p in different cancer cell types in both cell lines and clinical samples
are needed to determine whether these miRNAs can be used as potential cancer biomarkers. In
addition, studies examining the effects of miR-4719 and miR-6756-5p mimics and inhibitors on
cancer cell apoptosis need to be performed to validate if the mimic inhibitors could indeed be used
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as potential treatment options. Overall, this study elucidates the expression profile and role of miR4719 and miR-6756-5p as regulators of IL-24 in PCa. Our findings indicate that miR-4719 and
miR-6756-5p may regulate CRPC progression by targeting IL-24 expression and may be putative
biomarkers that differentiate between indolent and CRPC. Strategies to inhibit miR-4719 and miR6756-5p expression to increase IL-24 in PCa may have therapeutic efficacy in aggressive PCa.

6.4 Discussion
In this work, we elucidate novel pathways of IL-24 mechanism of action involving
translation initiation and PKA activation supporting IL-24’s role in potentiating ER stress to
specifically kill cancer cells. Additionally, we uncover putative microRNAs, miR-4719 and miR6756-5p, that regulate IL-24 mRNA expression and are differentially expressed in prostate cancer
and normal cells. While these findings contribute to the growing body of work describing IL-24
as an anti-cancer cytokine, the next step in understanding how IL-24 utilizes these pathways to kill
tumors would be to study these pathways in appropriate animal cancer models since our studies
have been limited to cancer cell lines.
Currently, much of the preclinical research efforts are concentrated on boosting the
delivery of IL-24 to a variety of tumor types and enhancing IL-24’s killing effect in combination
with small molecules or current cancer treatments. The types of viral vectors employed to deliver
the IL-24 gene has grown from adenoviruses to oncolytic viruses, which can selectively infect and
lyse tumor cells (He, Huang, Liu, & Xu, 2013; Lv, Su, Liang, Hu, & Yuan, 2016; Mao et al., 2018;
C.-J. Wang et al., 2012; Wu et al., 2009; C. W. Xiao et al., 2010; L. Xiao et al., 2010; L Zhao et
al., 2006; Lili Zhao et al., 2005). Even oncolytic viruses co-expressing IL-24 and miRNA genes
have been developed and tested in human liver cell lines (Lou et al., 2013). More recently, vaccinia
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viruses, which have historically been developed as vectors for infectious disease vaccines, are
being employed to treat breast cancer in vitro and in vivo (Deng et al., 2018; Yaghchi, Zhang,
Alusi, Lemoine, & Wang, 2015). Other methods of delivery utilize recombinant IL-24 fusion
proteins. A recombinant fusion protein consisting of IL-24 with targeting domain of transactivator
of transcription (TAT) and an ER retention sequence was shown to induce cancer-specific
apoptosis via ER stress in human bladder cancer, non-small cell lung cancer, and breast cancer cell
lines (J. Zhang et al., 2016). Researchers have also engineered recombinant protein fusing IL-24
to iRGD, a a novel tumor-specific peptide that is able to penetrate prostate tumors and internalize
in the cell with overall low toxicity in normal cells (J. Yang et al., 2019).
Ultimately, these studies of IL-24 have been vital for improving IL-24 overexpression and
specific cancer-killing activity in a more sustainable and targeted manner. Additional in vitro and
in vivo studies in different cancer cell types will further uncover molecules pertinent to IL-24’s
mechanism of action thus, revealing new approaches to enhance IL-24’s anti-angiogenic, antimetastatic and anti-proliferative properties. This will in turn support future clinical trials exploring
IL-24’s anti-cancer effect in multiple cancer cell types and not just melanoma, which past clinical
trials have been limited to (Cunningham et al., 2005; Tong et al., 2005).
Understanding the pathways that IL-24 activates or deactivates and how its expression
levels can be manipulated is not only relevant for the development of cancer therapeutics but also
for developing treatments for inflammatory diseases. IL-24 activity has been implicated in
autoimmunity, infectious disease response, wound repair, and vascular disease (Menezes et al.,
2018; Persaud et al., 2016). For example, for patients with inflammatory bowel disease (IBD), IL24 is protective in the colonic mucosa producing an anti-inflammatory effect (Andoh et al., 2009).
Thus, understanding how IL-24 expression can be upregulated to protect from IBD is worth
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considering. On the other hand, IL-24 has been found to be upregulated in patients suffering from
psoriasis and rheumatoid arthritis, suggesting that IL-24 may promote the pathogenesis of these
diseases (Kragstrup et al., 2017; Kumari et al., 2013; Sa et al., 2007). It is possible that miRNAs,
miR-4719 and miR-6756-5p, and their corresponding inhibitors described in this work could be
studied in inflammatory disease models to determine whether their expression status can be
exploited for new treatment approaches. Overall, IL-24 is indeed a multilayered pleiotropic
cytokine that has the potential to be used either as a therapeutic or a target in disease treatment.
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